Pharmaceuticals

Research Press Releases in Pharmaceuticals

Microcarrier Market
May, 2024

New York, May 2024: According to a new research study by Global Insight Services (GIS), the global Microcarrier Market is expected to grow rapidly over the next 10 years to reach a value of more than USD 4,207.3 million by 2033.

Microcarriers are tiny, typically spherical beads that provide a surface for the growth of anchorage-dependent cells. These cells, unlike suspension cells, require a physical substrate to attach to in order to proliferate. Microcarriers offer a dramatically increased surface area within bioreactors, enabling large-scale, high-density cell culture, which is essential for the production of cell-based therapies, vaccines, and other biological products.

Traditionally, microcarriers have been made of materials like polystyrene or glass. However, the field is rapidly evolving, with newer generations incorporating biological coatings, specialized surface chemistries, and even porous 3D structures to better mimic the natural cellular environment. This customization allows researchers to optimize cell attachment, growth, and even differentiation for specific cell types and applications.

The microcarrier market represents a specialized niche within the biotechnology and pharmaceutical sectors, dedicated to the manufacturing and utilization of microcarriers. These microscopic beads serve as a fundamental component in cell culture, offering a surface upon which adherent cells can thrive and propagate. By maximizing available surface area, microcarriers significantly augment the efficiency of cell growth processes, playing an essential role in various biomanufacturing endeavors.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20943

Microcarrier Market: Key Trends and Drivers

Growing popularity of biodegradable microcarriers for cell manufacturing

The limited availability of adult stem cells necessitates the development of cost-effective methods for their large-scale expansion ex vivo. Microcarriers, established tools in the biopharmaceutical industry, offer a solution by providing a vast surface area for adherent cell growth in stirred-tank bioreactors. However, conventional microcarriers pose a safety risk due to potential microparticle contamination in the final cell product, hindering their use in clinical trials and approved autologous stem cell therapies. Consequently, even in clinical settings, adult stem cells, like mesenchymal stem cells (MSCs), are often cultured in labor-intensive and poorly controlled two-dimensional tissue culture flasks.

The development of dissolvable or degradable microcarriers represents a significant leap forward in overcoming challenges associated with stem cell expansion. These novel microcarriers degrade in vivo or dissolve in vitro, eliminating the contamination risk associated with traditional microcarriers. This innovation paves the way for gentler cell harvesting methods that don’t rely on harsh enzymatic dissociation. Alternative methods could involve manipulating factors like pH, temperature, or biochemical changes in cell-adherent molecules, all while preserving cell viability and function. Depending on the degradation rate, cells grown on these dissolvable microcarriers can be harvested either by dissolving the carriers within the bioreactor or by directly implanting both cells and microcarriers at the site of injury. Studies have shown promising results with various dissolvable microcarrier platforms, including porous PLGA microcarriers for culturing human adipose stem cells.

Integration with 3D bioprinting

Bioprinting offers a revolutionary approach for fabricating living tissue constructs with customized architectures. This technology holds particular promise for generating complex tissues like osteochondral tissue, which features a zonal composition in the cartilage domain supported by subchondral bone. However, challenges remain in creating functional grafts of clinically relevant size. These challenges include incorporating cues for specific cell differentiation and generating sufficient cell numbers, which can be difficult to achieve with conventional cell culture techniques. A novel strategy for overcoming these limitations involves combining bioprinting with microcarrier technology. Microcarriers enable the large-scale expansion of cells while promoting the formation of multicellular aggregates and controlled cell phenotype. This study explores the potential of bioprinting cell-laden microcarriers for fabricating living tissue constructs.

The researchers utilized mesenchymal stromal cell (MSC)-laden polylactic acid (PLA) microcarriers, obtained via static culture or spinner flask expansion. These microcarriers were then encapsulated within a gelatin methacrylamide-gellan gum bioink. The study evaluated the printability of this composite material and demonstrated the feasibility of fabricating constructs with high cell concentration and viability. The successful application of microcarriers in bioprinting for tissue engineering signifies a potentially significant new market segment for the microcarrier industry. This approach could drive demand for microcarriers with specific properties tailored for bioprinting applications, such as biocompatible materials, controlled degradation rates, and surface modifications. The exploration of microcarriers for bioprinting represents a promising avenue for the microcarrier industry. As research in this field progresses, we can expect to see the development of specialized microcarriers that further enhance the capabilities of bioprinting for tissue engineering and regenerative medicine applications.

Microcarrier Market: Restraints and Challenges

High costs associated with cell biology research

The microcarrier market holds immense promise for advancements in cell therapy, tissue engineering, and other biopharmaceutical applications. However, a significant barrier to wider adoption lies in the high costs associated with cell biology research.

Academic research labs often operate on tight budgets, prioritizing cost-effective solutions for cell culture experiments. The initial investment in high-quality microcarriers, coupled with the potentially specialized equipment required for their use (e.g., bioreactors), can be a significant financial hurdle. This limited adoption in academic research hinders the broader exploration and development of microcarrier applications, which could ultimately benefit the entire market. Many novel cell therapies and tissue engineering approaches rely on efficient and scalable cell culture techniques. Microcarriers offer significant advantages in this regard, but the high upfront costs can slow down the translation of promising research findings into real-world applications. This delay in downstream development reduces the potential market size for microcarriers, as their full potential remains unrealized.

Biocompatibility and immunogenicity concerns

Despite the exciting potential of microcarriers for cell therapy and tissue engineering, their widespread adoption is hampered by lingering concerns regarding biocompatibility and immunogenicity. In the context of microcarriers for cell therapy and tissue engineering, biocompatibility refers to the ability of the microcarriers to coexist peacefully with the human body. It encompasses two main aspects – cytocompatibility and in vivo compatibility. Cytocompatibility refers to the compatibility of the microcarriers with the cells themselves. Ideally, the microcarriers shouldn’t harm, inhibit the growth, or alter the function of the cells they are intended to support. In vivo compatibility refers to the broader compatibility of the microcarriers within the body. They shouldn’t trigger an inflammatory response, be toxic to surrounding tissues, or leave behind harmful residues after cell harvest.

On the other hand, immunogenicity refers to the potential of the microcarriers to trigger an immune response in the body. The materials used to create the microcarriers might be recognized as foreign by the body’s immune system. This can lead to the activation of immune cells that attack and destroy the microcarriers. An ideal microcarrier would be non-immunogenic. This is crucial for the safety and efficacy of cell therapy.

Microcarrier Market Report Findings

https://www.globalinsightservices.com/reports/microcarrier-market

The Collagen-based segment is anticipated to dominate the market during the forecast period

Based on material segment, the market is bifurcated into collagen-based, gelatin-based, hyaluronic acid-based, polystyrene-based, dextran-based, and modified polyvinyl alcohol. The Collagen-based segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 846.3 Million in 2023 and it is anticipated to grow further to USD 1,686.2 Million by 2033, at a CAGR of 7.1% during the forecast period. Collagen-based materials are substances derived from collagen, a structural protein found in connective tissues such as skin, bone, and cartilage. These materials are utilized in various biomedical applications, including tissue engineering, wound healing, and drug delivery. Examples include collagen scaffolds, films, hydrogels, and microcarriers, which provide a biocompatible and biodegradable platform for cell culture and tissue regeneration. Notable applications range from promoting skin regeneration in wound dressings to serving as matrices for cartilage repair in orthopedic surgeries. Growth factor such as collagen possesses excellent biocompatibility, mimicking the natural extracellular matrix (ECM) environment in which cells thrive. This similarity facilitates cell adhesion, proliferation, and differentiation, promoting enhanced cell growth and productivity

The Two-Dimensional segment is anticipated to dominate the market during the forecast period

Based on technology segment, the market is bifurcated into two-dimensional, and three-dimensional. The Two-Dimensional segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 1,609.2 Million in 2023 and it is anticipated to grow further to USD 3,076.3 Million by 2033, at a CAGR of 6.7% during the forecast period. Two-dimensional (2D) technology remains a fundamental aspect of the global microcarrier market, offering a traditional yet effective approach to cell culture and bioprocessing. In 2D cell culture, cells are grown as monolayers on flat surfaces, such as tissue culture plates or dishes, enabling easy observation and manipulation under a microscope. While 2D culture lacks the physiological relevance of three-dimensional (3D) environments, it remains widely used due to its simplicity, cost-effectiveness, and compatibility with high-throughput screening and analysis techniques. Key advantages of 2D technology in the microcarrier market such as versatility and adaptability to a wide range of cell types and applications. From immortalized cell lines to primary cells and stem cells, 2D culture systems can accommodate diverse cell populations, making them invaluable tools in basic research, drug discovery, and bioproduction.

The Regenerative Medicine segment is anticipated to dominate the market during the forecast period

Based on application, the market is segmented into regenerative medicine, cultured meat production, vaccine production, cell therapy, biologics manufacturing, stem cell research, and tissue engineering. The Regenerative Medicine segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 563.7 Million in 2023 and it is anticipated to grow further to USD 1,123.2 Million by 2033, at a CAGR of 7.1% during the forecast period. Regenerative medicine is a pioneering field aiming to restore tissues through cellular therapies, tissue engineering, and biomaterials. In the global microcarrier market, microcarriers are crucial for expanding therapeutic cells. They provide scaffolding for cells to adhere and proliferate, mimicking the extracellular matrix, vital for cellular viability and function. Microcarriers are pivotal in producing therapeutic cells like MSCs, chondrocytes, and cardiomyocytes for transplantation and tissue repair. They can be engineered to promote specific cell differentiation pathways, enhancing tissue regeneration. Additionally, microcarriers act as delivery vehicles for targeted cell administration, improving therapy outcomes. Investments in regenerative medicine drive demand for advanced microcarrier technologies. Research focuses on optimizing formulations, surface modifications, and bioprocessing protocols, accelerating market growth.

The Bioreactors segment is anticipated to dominate the market during the forecast period

Based on equipment, the market is segmented into bioreactors, cell culture vessels, centrifuges, incubators, cell counters, separation systems, storage systems, and processing systems. The Bioreactors segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 589.0 Million in 2023 and it is anticipated to grow further to USD 1,176.4 Million by 2033, at a CAGR of 7.2% during the forecast period. Bioreactors are indispensable in the microcarrier market, providing controlled environments for cell cultivation and expansion. These devices regulate temperature, pH, oxygen levels, and nutrient supply, ensuring optimal cell growth and functionality. Ranging from benchtop to industrial scales, bioreactors cater to academic research, biopharmaceutical manufacturing, and regenerative medicine. Their scalability and reproducibility facilitate commercial cell and biologic production, meeting the demand for therapies and vaccines. Customizable designs accommodate various cell types and culture formats, optimized for nutrient delivery and growth. Integrated monitoring systems enable real-time process control, enhancing efficiency and automation. Increasing bioreactor adoption drives cell production growth. Research focuses on optimizing design and integration with microcarrier technologies, fostering innovation. As bioreactors evolve, they play pivotal roles in biomedical research and therapy development globally

The Small(<1,000 µm) segment is anticipated to dominate the market during the forecast period

Based on size of microcarriers segment, the market is bifurcated into small (<1,000 µm), medium (1,000–2,000 µm), and large (>2,000 µm). The Small(<1,000 µm) segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 1,179.8 Million in 2023 and it is anticipated to grow further to USD 2,309.9 Million by 2033, at a CAGR of 6.9% during the forecast period. The small size category of microcarriers, typically measuring less than 1,000 µm in diameter, represents a significant and versatile segment within the global microcarrier market. These microcarriers offer several advantages, including high surface area-to-volume ratios, efficient nutrient exchange, and enhanced cell attachment and proliferation kinetics. Their small size enables greater control over cell density and distribution, facilitating uniform cell growth and maximizing culture efficiency in bioprocessing applications. Small-sized microcarriers is their compatibility with various cell types, including adherent cell lines, stem cells, and primary cells. The miniature dimensions of these microcarriers allow for close proximity between cells and the surrounding culture medium, promoting cell-cell interactions and paracrine signaling. This feature is particularly advantageous for applications in cell therapy, tissue engineering, and regenerative medicine, where precise control over cellular microenvironments is essential for therapeutic efficacy.

The Biopharmaceutical Companies segment is anticipated to dominate the market during the forecast period

Based on end-user segment, the market is bifurcated into biopharmaceutical companies, contract research organizations, and academic and research institutes. The Biopharmaceutical Companies segment is anticipated to dominate the market during the forecast period. The segment was valued at USD 1,142.9 Million in 2023 and it is anticipated to grow further to USD 2,254.8 Million by 2033, at a CAGR of 7.0% during the forecast period. Biopharmaceutical companies are key players in the global microcarrier market, leveraging microcarrier technology to produce a wide range of biologics, including monoclonal antibodies, vaccines, recombinant proteins, and cell-based therapies. These companies utilize microcarriers in cell culture and bioprocessing operations to efficiently expand and manipulate cells, optimize protein expression, and enhance product yield and quality. By leveraging microcarrier technology, biopharmaceutical companies can achieve higher productivity, scalability, and cost-effectiveness in the production of biologics compared to traditional cell culture methods. Microcarriers can support the cultivation of different cell types, including mammalian cells, insect cells, and plant cells, enabling the production of a wide range of biologic drugs, from monoclonal antibodies and therapeutic proteins to viral vaccines and cell-based therapies. This versatility allows biopharmaceutical companies to address unmet medical needs across multiple disease areas and patient populations.

The North America region is anticipated to dominate the market during the forecast period

Based on region, the market is studied across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. The North America region is anticipated to dominate the market during the forecast period. The region was valued at USD 842.8 Million in 2023 and it is anticipated to grow further to USD 1,637.4 Million by 2033, at a CAGR of 6.9% during the forecast period. North America enhanced a robust biopharmaceutical industry, characterized by extensive research and development activities, particularly in cell therapy, regenerative medicine, and vaccine production. Microcarriers serve as essential tools in these processes, providing a three-dimensional environment for cell culture, enhancing cell growth, and enabling large-scale production. As companies in the region continue to invest in innovative biopharmaceutical solutions, the demand for microcarriers as a critical component of bioprocessing workflows has surged. For instance, in January 2022, Cellino Biotech, a cell therapy manufacturing company, raised USD 80 million in Series A financing round. Cellino plans to expand access to stem cell-based therapies by building the first autonomous human cell foundry by 2025. As the applications of stem cell technologies in the treatment of diseases have ultimately increased, so has the overall adoption rate of these technologies across the region. this factor ultimately driving the demand for microcarriers as essential components in cell culture processes, consequently increasing the growth of the North America microcarrier market.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20943

Competitive Landscape

The microcarrier market report includes players such as Thermo Fisher Scientific, Merck KGaA, Sartorius AG, Corning Incorporated, Lonza Group, GE Healthcare, Eppendorf AG, HiMedia Laboratories, Incyte Corporation, Kuraray, Bio-Rad Laboratories, Takara Bio, Polysciences Inc., Novozymes, PromoCell GmbH, TCB, Teijin Ltd, DenovoMatrix GmbH, Percell Biolytica AB, and Asahi Kasei Corporation among others.

Recent Developments

  • In April 2024, Thermo Fisher Scientific Inc., the world leader in serving science, has introduced the Gibco™ CTS™ OpTmizer™ One Serum-Free Medium (CTS OpTmizer One SFM), a novel animal origin-free (AOF) formulation designed specifically for clinical and commercial cell therapy manufacturing to deliver increased scalability and performance of T cell expansion.
  • In April 2024, The life science group Sartorius and U.S.-based startup The Well Bioscience have agreed to partner on the further development of hydrogels and bioinks tailored to produce 3D advanced cell models for drug discovery workflows.
  • In April 2024, GE HealthCare has launched the Voluson Signature 20 and 18 ultrasound systems, integrating AI, advanced tools, and ergonomic design to enhance diagnostics in women’s health. These systems expedite exams and improve accuracy through AI-driven features like voice control and automated measurements.
  • In March 2024, Merck, known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (Nasdaq: HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon’s common stock will no longer be publicly traded or listed on the Nasdaq Stock Market.
  • In March 2024, Lonza Signs Agreement to Acquire Large-Scale Biologics Site in Vacaville (US) from Roche.
Microcarrier Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Microcarrier Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of Microcarrier Market in terms of revenue ($Million).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Microcarrier Market.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country market analysis is also presented in this report.
  • Analytical depiction of the Microcarrier Market along with the current trends and future estimations to depict imminent investment pockets. The overall Microcarrier Market opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Microcarrier Market are also analysed.
Market Segments

By Material Type

  • Collagen-based
  • Gelatin-based
  • Hyaluronic Acid-based
  • Polystyrene-based
  • Dextran-based
  • Modified Polyvinyl Alcohol

By Application

  • Regenerative Medicine
  •  Cultured Meat Production
  • Vaccine Production
  • Cell Therapy
  • Biologics Manufacturing
  • Stem Cell Research
  • Tissue Engineering

By End-User

  • Biopharmaceutical Companies
  • Contract Research Organizations
  • Academic and Research Institutes

By Equipment

  • Bioreactors
  • Cell Culture Vessels
  • Centrifuges
  • Incubators
  • Cell Counters
  • Separation Systems
  • Storage Systems
  • Processing Systems

By Technology

  • Two-Dimensional
  • Three-Dimensional

By Size of Microcarriers

  • Small (<1,000 µm)
  • Medium (1,000–2,000 µm)
  • Large (>2,000 µm)

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa
Key Players
Read More

Personalized Psychiatry Market
April, 2024

New York, March 2024: According to a new research study by Global Insight Services (GIS), the global Personalized Psychiatry Market is expected to grow rapidly over the next 10 years to reach a value of more than USD 11.2 billion by 2033.

Personalized psychiatry is an approach to mental health treatment that takes into account an individual’s unique characteristics, history, and lifestyle. It is based on the idea that mental health is not a one-size-fits-all approach. Instead, personalized psychiatry is tailored to an individual’s specific needs and goals. Personalized psychiatry is an evidence-based approach that combines the latest research in neuroscience, psychiatry, and psychotherapy to create a customized treatment plan for each patient. This includes a comprehensive assessment of the individual’s mental health, lifestyle, and biological factors. The assessment includes a review of the patient’s medical, psychological, and social history, as well as an evaluation of their symptoms and current functioning. From this assessment, a personalized treatment plan is created that is tailored to the individual’s needs and goals.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS26608

Personalized Psychiatry Market: Key Trends and Drivers

The key trends in personalized psychiatry technology include:

1. Digital Mental Health: Digital mental health technology is a rapidly growing field that uses digital tools to improve mental health care. This technology includes apps and other digital tools that can be used to monitor patient behavior, provide feedback, and deliver interventions. Digital mental health technology is helping to improve access to mental health services, reduce stigma, and provide care in a more convenient and cost-effective way.

2. Wearable Technology: Wearable technology is being used to monitor physical and mental health. This technology can be used to track vital signs, sleep patterns, and physical activity, which can help clinicians better understand a patient’s health and tailor treatments accordingly. Wearable technology is also being used to provide real-time feedback to patients to help them manage their mental health.

3. Artificial Intelligence: Artificial intelligence (AI) is being used to help clinicians better diagnose and treat mental health disorders. AI can be used to analyze patient data and provide insights to clinicians that can help them make more informed decisions about treatment. AI is also being used to identify patterns in patient behavior and provide more personalized interventions.

4. Smartphone Technology: Smartphone technology is being used to improve the delivery of mental health services. Smartphone apps can be used to monitor patient behavior, provide feedback, and deliver interventions. Smartphone technology is also helping to reduce stigma around mental health and provide more convenient care options.

These trends are helping to improve access to mental health services, reduce stigma, and provide more personalized care. As personalized psychiatry technology continues to evolve, it will become increasingly important for clinicians to understand the potential benefits and risks associated with this technology. By understanding the potential benefits and risks, clinicians can ensure that they are using this technology in the most effective and ethical way possible.

The key drivers of personalized psychiatry are:

1. Increasing Prevalence of Mental Health Disorders: Mental health disorders have been on the rise in recent years, with an estimated one in five adults in the United States experiencing a mental disorder during any given year. As such, there is an increased demand for more personalized care for mental health disorders.

2. Advances in Technology: Technology has enabled the development of new diagnostic tools and treatments that allow for more personalized care. For example, genetic testing has become increasingly accessible and can help identify genetic markers that can be used to personalize treatments.

3. Shift in Attitudes Toward Mental Health: There has been a shift in attitudes toward mental health in recent years, with mental health being viewed more positively and as something that should be taken seriously. This shift has helped to create a more open discussion about mental health and has encouraged people to seek help and treatment.

4. Increased Focus on Evidence-Based Treatments: There has been an increased focus on evidence-based treatments in recent years, with more emphasis being placed on treatments that are proven to be effective. Evidence-based treatments are often tailored to the individual, allowing for more personalized care.

5. Increased Availability of Mental Health Services: As the focus on mental health has increased, so has the availability of mental health services. This has made it easier for people to access the care they need, including personalized treatments.

Personalized Psychiatry Market: Restraints and Challenges

The key restraints and challenges in Personalized Psychiatry market include the lack of adequate data and information, cost of research and development, and regulatory and ethical issues.

Lack of Adequate Data and Information:

Personalized psychiatry relies heavily on data and information about the patient, including their genetic makeup, medical history, lifestyle, and environment. Without access to adequate data and information, it is difficult for psychiatrists to accurately diagnose and treat patients. Additionally, due to the complexity of the human brain and the lack of understanding of its functioning, psychiatrists often rely on trial and error when prescribing treatments, which can lead to misdiagnosis and mistreatment.

Cost of Research and Development:

Personalized psychiatry requires significant research and development in order to develop and refine treatments. This involves the use of sophisticated technology, such as brain imaging, genetic sequencing, and machine learning algorithms. These processes are expensive and require significant amounts of money to develop and refine. Additionally, the cost of collecting and analyzing data is also expensive, as it requires specialized personnel and equipment.

Regulatory and Ethical Issues:

Personalized psychiatry is still relatively new, and as such, is not yet fully regulated. This can lead to the potential misuse of data and information, as well as the potential for discrimination and privacy violations. Additionally, there are ethical considerations to be taken into account, such as the potential for psychiatrists to be biased based on their own beliefs and values.

Personalized Psychiatry Market Report Findings

https://www.globalinsightservices.com/reports/personalized-psychiatry-market

The genomics segment is anticipated to dominate the market during the forecast period

By product type, the market is divided into software, genomics, digital therapeutics. The genomics segment has the highest market share in 2023 and the digital therapeutics is expected to be the fastest growing segment in the coming years, due to increase in the usage of digital devices in healthcare industry. Advancements in genomic technologies have enabled the identification of genetic variations associated with psychiatric disorders, facilitating personalized treatment approaches. Genomic testing allows for the analysis of an individual’s genetic makeup to determine their predisposition to certain mental health conditions and their response to specific medications. Additionally, the growing availability and affordability of genomic testing kits have expanded access to personalized psychiatric care for patients. Moreover, ongoing research in genomics continues to uncover novel biomarkers and therapeutic targets, driving innovation and growth in the genomics product type segment of the Personalized Psychiatry market.

The depression and anxiety segment is anticipated to dominate the market during the forecast period

Based on condition, it is bifurcated into depression & anxiety, bipolar disorder, addiction, dementia, other conditions. The depression and anxiety segment has the market in the 2023, and it is further anticipated to increase at a rapid rate in the coming years. The growing recognition of the heterogeneity within these conditions, with varying underlying causes and treatment responses among individuals. This recognition has fueled the demand for personalized approaches to diagnosis and treatment. Additionally, advancements in neuroimaging, genetic testing, and biomarker identification have provided insights into the biological mechanisms underlying depression and anxiety, enabling more targeted interventions. Moreover, the increasing prevalence of these conditions worldwide, coupled with rising awareness and destigmatization efforts, has led to a greater demand for personalized psychiatric care tailored to individual needs.

The patients segment is anticipated to dominate the market during the forecast period

On the basis of end-user, the market is classified into mental health professionals, patients, healthcare providers. The patients segment has dominated the segmental growth of the end-user segment in 2023. Further the mental health professionals segment is growing at a faster rate. There is a growing emphasis on patient-centered care and individualized treatment approaches in mental health. Patients are increasingly seeking personalized psychiatric interventions that cater to their unique needs, preferences, and genetic makeup. Additionally, advancements in digital health technologies, such as telepsychiatry and mobile health apps, have empowered patients to take a more active role in managing their mental health and accessing personalized interventions remotely. Moreover, the rising awareness and destigmatization of mental health issues have encouraged more individuals to seek help and participate in personalized psychiatric programs tailored to their specific conditions and circumstances.

The North America region is anticipated to dominate the market during the forecast period

Region-wise, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The North American region accounted for the majority of the market share during the forecast period followed by Europe. The high prevalence of mental health disorders in North America, driving the demand for personalized psychiatric interventions. Additionally, the region boasts advanced healthcare infrastructure and research capabilities, facilitating the development and adoption of personalized medicine approaches. Moreover, supportive government policies and initiatives, along with robust investments in healthcare innovation, contribute to the growth of the Personalized Psychiatry market in North America. Furthermore, increasing awareness and destigmatization efforts surrounding mental health issues in the region encourage individuals to seek personalized psychiatric care, further fueling market expansion.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS26608

Competitive Landscape

The global clinical trails market includes players such as COMPASS Pathways (UK), Mindstrong Health (US), Pear Therapeutics (US), Akili Interactive (US), Empatica (US), Neuroverse (US), Cogito (France), Kaia Health (Germany), Sooma (US), GenoMind (US)

Recent Developments

  • In January 2024, Being Health, a modern mental health practice founded by psychiatrists, is launching today in New York City. The practice aims to offer a comprehensive range of mental health services, including psychiatry, psychotherapy, novel treatments like ketamine infusion therapy, functional medicine, and wellness services such as acupuncture and nutrition, all in one place. Being Health has received $5.4 million in funding from 18 Park and HDS Capital.
  • In November 2023, Salus, a mental health platform, has successfully completed a $4.7 million Seed investment round, bringing its total fundraising since its inception to over $5.5 million. Salus’ platform stands out as the only comprehensive and personalized mental health product in the region. It aims to make preventive mental health services affordable and accessible. By offering a science-backed and measurable approach, Salus encourages employers to invest in their employees’ mental health, showing a significant return on investment and improving employee well-being on a large scale. The platform is also considering expanding its services to include nutrition and physical health. Leading this round is Northzone, with additional contributions from 500 Emerging Europe, Pitchdrive, and İş Bank’s CVC arm. Existing investors Collective Spark and Wamda Capital have also reinvested, along with various angel investors.
  • In August 2023, Likeminded, a startup based in Berlin focusing on mental health solutions, has secured €5.9 million in seed funding from notable investors like Holtzbrinck Digital and existing investor Heartcore Capital. The main aim of Likeminded’s digital platform is to offer personalized support for employees in corporate settings, with the goal of preventing overwork and burnout. Companies such as Jack Wolfskin, Oliver Wyman, and sennder have already seen positive results from using the platform, leading to increased employee retention and satisfaction. The new funding will be crucial for Likeminded to expand its business and achieve its goal of becoming Europe’s leading mental health solutions platform. The focus will be on improving AI-driven personalization and implementing scalable formats. With strong investor support, Likeminded is well-positioned to make a significant impact on mental health in the corporate world.
Personalized Psychiatry Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Personalized Psychiatry Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Personalized Psychiatry Market in terms of revenue ($Million).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Personalized Psychiatry industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country, market analysis is also presented in this report.
  • The Personalized Psychiatry Market Study comprises an analysis of 23 countries. The research also encompasses a segment analysis of every country in terms of value (USD Million) throughout the study period.
  • Analytical depiction of the Personalized Psychiatry Market along with current trends and future estimations to depict imminent investment pockets. The overall Personalized Psychiatry industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Personalized Psychiatry Market are also analyzed.
  • The report also involves market strategy factors such as the ANSOFF Matrix, 4Ps Model, Demand-Supply Analysis, Competition Product Analysis, Recent Developments, Consumer Buying Interest, and Supply Chain Analysis among others.
Market Segments

By Product Type

  • Software
  • Genomics
  • Digital Therapeutics

By Condition

  • Depression & Anxiety
  • Bipolar Disorder
  • Addiction
  • Dementia
  • Other Conditions

By End-User

  • Mental Health Professionals
  • Patients
  • Healthcare Providers

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa
Key Players
Read More

Clinical Trials Market
March, 2024

New York, March 2024: According to a new research study by Global Insight Services (GIS), the global Clinical Trials market is expected to grow rapidly over the next 10 years to reach a value of more than USD 89.6 billion by 2033.

A clinical trial is a research study that tests a new medical approach, device, medication, or other treatment. Clinical trials are used to determine whether new medical approaches are safe and effective. Clinical trials are conducted in phases. The first phase is designed to assess the safety of the new approach. The second phase is designed to assess its effectiveness.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20584

Clinical Trials Market: Key Trends and Drivers

There are a few key trends in clinical trials technology that are worth mentioning.

First, there is a trend towards using more patient-centric methods in clinical trials. This means that instead of relying on traditional methods like paper-based questionnaires, clinical trials are increasingly using digital tools to collect data from patients.

Another trend is the use of mobile technologies in clinical trials. Mobile technologies can be used to collect data from patients, to track their progress, and to remind them of appointments.

The key drivers of clinical trials market are the high cost of clinical trials, the need for large patient populations, and the need for long-term follow-up.

The high cost of clinical trials is a result of the need for large patient populations and the need for long-term follow-up. The need for large patient populations is a result of the fact that clinical trials are often conducted in multiple phases, each of which requires a different number of patients. The need for long-term follow-up is a result of the fact that clinical trials often involve new treatments that need to be evaluated over time.

Clinical Trials Market: Restraints and Challenges

The key restraints and challenges in the clinical trials market are the high cost of clinical trials, the lengthy timelines for clinical trials.

The high cost of clinical trials is a major restraint for the clinical trials market. The cost of a clinical trial can vary depending on the type of clinical trial, the number of patients involved, and the duration of the trial.

The lengthy timelines for clinical trials is another major challenge for the clinical trials market. A typical clinical trial can take several years to complete, from the initial planning stages to the final analysis of data.

Clinical Trials Market Report Findings

https://www.globalinsightservices.com/reports/clinical-trials-market

The Phase 2 segment is anticipated to dominate the market during the forecast period

By phase, the market is divided into phase 1, phase 2, phase 3, and phase 4. The phase 2 segment has dominated the market in 2023 and the phase 4 is expected to be the fastest growing segment in the coming years. Phase 2 trials play a crucial role in assessing the safety and efficacy of potential treatments following initial safety testing in Phase 1. This phase provides valuable data on dosage, side effects, and preliminary effectiveness, guiding further development decisions. Secondly, the growing emphasis on precision medicine and personalized treatments necessitates robust Phase 2 trials to identify patient subgroups that may benefit most from the experimental therapy. Additionally, regulatory agencies often require successful Phase 2 results for advancing to larger Phase 3 trials, underscoring the significance of this phase in the drug development process.

The Expanded Access Study segment is anticipated to dominate the market during the forecast period

On the basis of study design, it is bifurcated into interventional study, observational study, and expanded access study. The expanded access study has dominated the segmental share in 2023 and the interventional design is expected to be the fastest growing segment during the coming years. This is because the heightened patient advocacy and regulatory initiatives have increased awareness and demand for expanded access programs, particularly for patients with life-threatening or serious diseases lacking viable treatment options. These programs offer access to investigational therapies outside of traditional clinical trial settings, providing hope for patients and their families. Furthermore, the pharmaceutical companies recognize the potential benefits of expanded access studies in generating real-world evidence, enhancing product visibility, and fostering goodwill within the medical community. Moreover, expanded access programs align with ethical imperatives to prioritize patient welfare, making them a valuable component of drug development strategies.

The Oncology segment is anticipated to dominate the market during the forecast period

Based on therapeutic area, the market is classified into autoimmune disease, oncology, cardiology, and others. The oncoloyg segment dominated the market in 2023 and the autoimmune disease is expected to be the fastest growing segment in the coming years. The growth is attributed to the rising global incidence of cancer and the continuous search for effective treatments propel the demand for oncology clinical trials. Pharmaceutical companies, biotechs, and academic institutions are investing heavily in oncology research to develop innovative therapies targeting various types and stages of cancer. Moreover, advances in molecular biology, genomics, and immunotherapy have revolutionized cancer treatment paradigms, creating opportunities for novel therapeutic interventions. Additionally, regulatory agencies’ expedited pathways for oncology drug approvals incentivize sponsors to conduct clinical trials in this area, driving further growth and innovation in oncology research.

The North America region is anticipated to dominate the market during the forecast period

Region-wise, it is segmented into North America, Europe, Asia Pacific, and Rest of the World. The North America holds a major market share for Clinical Trials market and is expected to continue its stronghold for a few more years. The growth is attributed to the region’s robust healthcare infrastructure and skilled workforce attracts pharmaceutical and biotechnology companies to conduct trials. Secondly, favorable regulatory frameworks and streamlined approval processes encourage research and development activities. Thirdly, the increasing prevalence of chronic diseases and the demand for innovative treatments stimulate the need for clinical trials. Additionally, advancements in technology and data analytics enhance trial efficiency and effectiveness. Moreover, collaborations between academic institutions, research organizations, and industry players facilitate access to diverse patient populations and expertise, further driving the growth of the clinical trials market in North America.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20584

Competitive Landscape

The global clinical trails market includes players such as Pfizer, Clinipace, Novo Nordisk A/S, Eli Lilly and Company, Syneos Health, PRA Health Sciences, ICON Plc, Charles River Laboratory, Pharmaceutical Product Development  LLC, and PAREXEL International Corporationamong others.

Recent Developments

  • In January 2024, QuantHealth has received a strategic investment from Accenture Ventures to accelerate the adoption of AI-powered clinical trial simulations, aiming for more cost-effective drug development. This funding, along with contributions from an undisclosed contract research organization and other investors, totals QuantHealth’s Series A round to $17 million. The investment will assist QuantHealth in advancing its platform designed to simulate clinical trials in the cloud, aiding pharmaceutical and biotech companies in swiftly developing treatments for patients. QuantHealth’s platform, incorporating AI technology, is trained on a vast dataset of 350 million patients, biomedical knowledge graphs, and study data. The platform is anticipated to provide an 86% accuracy rate in predicting trial outcomes using the binary endpoint metric.
  • In January 2024, Novartis, along with companies like Eli Lilly, has invested in AI technology developer Yseop. This investment is aimed at automating parts of clinical trial report writing to accelerate drug development efforts.
  • In November 2023, Julius Clinical Research, a prominent clinical Contract Research Organization (CRO) offering trial services and real-world evidence studies to biopharma sponsors, is pleased to announce a majority recapitalization by Ampersand Capital Partners. This investment and partnership with Ampersand will allow the company to broaden its scientific knowledge and therapeutic capabilities. Additionally, it will help Julius Clinical Research expand its presence in Europe and North America, facilitating the growth of its CRO services.
Clinical Trials Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Clinical Trials Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Clinical Trials Market in terms of revenue ($Million).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Clinical Trials industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country, market analysis is also presented in this report.
  • The Clinical Trials Market Study comprises an analysis of 23 countries. The research also encompasses a segment analysis of every country in terms of value (USD Million) throughout the study period.
  • Analytical depiction of the Clinical Trials Market along with current trends and future estimations to depict imminent investment pockets. The overall Clinical Trials industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Clinical Trials Market are also analyzed.
  • The report also involves market strategy factors such as the ANSOFF Matrix, 4Ps Model, Demand-Supply Analysis, Competition Product Analysis, Recent Developments, Consumer Buying Interest, and Supply Chain Analysis among others.

Global Clinical Trials Market Segmental Overview

Market Segments

By Phase

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4

By Study Design

  • Interventional Design
  • Expanded Access Study
  • Observational Study

By Therapeutic Area

  • Autoimmune disease
  • Oncology
  • Cardiology
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • Italy
    • Spain
    • France
    • UK
    • Russia
    • Switzerland
    • Denmark
    • Finland
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • South Korea
    • Japan
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Rest of APAC
  • Rest of the World
    • Latin America
    • Middle East
    • Africa
Key Players
Read More

Global Microcarrier Market Database
March, 2024

New York, March 2024: Global Microcarrier Market Database is a new subscription offering from Global Insight Services that offers tracking of pharma and biotech companies that use microcarriers. Subscribers to this service receive access to updates to the company database every month.

Microcarriers are small, typically spherical particles made from materials such as dextran, polystyrene, or glass, designed to support the growth of anchorage-dependent cells in bioreactors. These cells require a surface to adhere to for growth and proliferation, which is provided by microcarriers. In biotechnology and cell culture applications, microcarriers serve as a substrate for cells to attach to and grow in suspension culture systems, allowing for the production of large quantities of cells in a controlled environment. Microcarriers are commonly used in the production of vaccines, therapeutic proteins, and other biopharmaceuticals, as well as in tissue engineering and regenerative medicine research. They offer advantages such as scalability, increased surface area for cell attachment, and ease of handling during cell culture processes.

Key Benefits

  • Provides detailed information on all pharma and biotech companies that use microcarriers globally on a live basis.
  • Assess competitor actions and gain insight into your market positioning.
  • Provides detailed data on companies, including their name, headquarters location, year of incorporation, ticker symbol, and stock exchange listing.
  • Offers insights into the biotechnology and pharmaceutical industries, including key players and their market presence.
  • Helps track trends in microcarrier applications across different sectors, including life sciences, genomics, drug development, gene therapies, ophthalmology, antibody discovery, and drug development.
  • Enables comparison of companies within the microcarrier market, aiding in understanding their strengths, weaknesses, and competitive positioning.
  • Supports research and development efforts by providing insights into companies involved in microcarrier technology and their areas of focus.

Database Coverage

  • More than 1100 companies are listed and more are being added daily
  • Around 30 countries listed
  • Company Information
  • Company Name
  • Headquarter
  • Year of Incorporation
  • Ticker Symbol
  • Stock Exchange
  • Industry Type
  • Microcarrier Application

Major Microcarrier Manufacturers

  • Thermo Fisher Scientific
  • Corning Incorporated
  • Merck KGaA
  • Sartorius AG
  • Cytiva
  • Pall Corporation (a Danaher company)
  • Greiner Bio-One
  • FiberCell Systems
  • Repligen Corporation
  • Irvine Scientific
  • CellGenix GmbH
  • Lonza Group
  • Takara Bio Inc.
  • Kuraray Co., Ltd.
  • FUJIFILM Holdings Corporation
  • Eppendorf SE

Key Microcarrier Users

  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Hoffmann-La Roche Ltd
  • AstraZeneca
  • Sanofi Group
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • AbbVie Inc.
  • Biogen
  • Gilead Sciences, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Vertex Pharmaceuticals Incorporated
  • Moderna, Inc.
  • BioMarin
  • Incyte Corporation
  • Alnylam Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.

By Industry Type

  • Pharmaceuticals
  • Biotechnology
  • Others

By Microcarrier Application

  • Cell Therapy
  • Gene Therapy
  • Drug Development & Drug Discovery
  • Stem Cells
  • Tissue Engineering
  • Regenerative Medicines
  • Vaccine Production
  • Biopharmaceutical Production
  • Therapeutics
  • Others

By Region

  • North America
    • The United States
    • Canada
  • Europe
    • Spain
    • The United Kingdom
    • Switzerland
    • Germany
    • Ireland
    • The Netherlands
    • Denmark
    • Belgium
    • Luxembourg
    • Sweden
    • France
    • Austria
    • Italy
    • Finland
    • Norway
    • Slovenia
    • Scotland
    • The Czech Republic
    • Russia
  • Asia-Pacific
    • China
    • South Korea
    • Australia
    • India
    • Japan
    • Taiwan
    • Singapore

Recent Developments

  • In January 2024, Bio-Techne Corporation exhibits its cell and gene therapy solutions at Phacilitate’s Advanced Therapies Week from January 16–19 at the Miami Beach Convention Centre. Their booth features FluorokinesTM proteins, multi-color flow cytometry panels for CAR-T and CAR-NK cell analysis, RNAscopeTM assays for therapeutic visualization, GMP media and liquid cytokines for immune cell expansion, and automated instruments for product characterization and in vivo monitoring.
  • In January 2024, The Israeli biotechnology startup, Pluri unveiled the establishment of PluriCDMO, a fresh business segment dedicated to delivering cell therapy manufacturing services as a Contract Development and Manufacturing Organization (CDMO). Integral to this expansion is a state-of-the-art, 47,000-square-foot facility adhering to Good Manufacturing Practice (GMP) standards, aimed at bolstering cell therapy production within the company.
  • In October 2023, Kuraray Co., Ltd. developed PVA hydrogel microcarriers tailored for use in regenerative medicine cell cultures. Scheduled for release in January 2024 in Japan and subsequently in other nations, beginning with the US, these microcarriers offer a novel approach. The PVA hydrogel microcarriers facilitate efficient cell detachment and recovery as cells adhere to and proliferate on their surface upon placement in the bioreactor for large-scale cell culture. Demonstrating enhanced cell culture efficacy, our microcarriers have undergone rigorous safety testing and exhibit resilience even under bioreactor agitation.
  • In October 2023, Semarion Ltd., a spin-out from the University of Cambridge’s Cavendish Laboratory, introduced its Early Adopter Programme for the SemaCyte Microcarrier Platform. This initiative merges materials engineering and cell biology to tackle unmet requirements in drug screening. By allowing small cell colonies to be transported and frozen while still adhering, the platform enhances data yield per experiment and reduces the resource burden of in vitro drug discovery. This addresses existing constraints related to adherent cell culture and assay workflows.
  • In July 2023, Cytoniche Bioscience’s 3D TableTrix® Microcarriers, designated with file number 037798, obtained FDA Type II Drug Master File (DMF) registration. This enables their utilization as active pharmaceutical ingredients (APIs), expanding their role beyond pharmaceutical excipients. These microcarriers can now contribute to medication formulations and may exert pharmacological effects or influence the human body’s composition and functionality.
  • In June 2023, Teijin Frontier developed an innovative nonwoven microcarrier technology that differs from traditional weaving methods. This advancement, originating from the fiber and product conversion division of the Teijin Group, is designed to streamline the production of extensive cell cultures of superior quality. The primary function of this novel scaffolding material is to enhance three-dimensional adhesion and growth for various types of cells.
  • In March 2023, Soluble microcarriers serve as scaffolding agents in cell culture methodologies, facilitating the generation of cell and gene-based products, exosomes, biopharmaceuticals, and cultured meat. Developed by Dai Nippon Printing Co., Ltd. (DNP) and Hyperion Drug Discovery Co., Ltd. (HDD), known for their advancements in regenerative medicine and gene therapy, these microcarriers play a pivotal role in supporting various applications within the field.
Read More

Biosimilars Market
February, 2024

New York, February 2024: According to a new research study by Global Insight Services (GIS), the Biosimilars Market is expected to grow rapidly over the next 10 years and it is expected to reach a CAGR 13.8% during the forecast period.

Biosimilars are biological products that are approved by the FDA to be highly similar to an already-approved biological product, known as a reference product. Biosimilars are also called subsequent entry biologics (SEBs). Biosimilars can be used to treat the same conditions as the reference product.

The FDA has a pathway for approving biosimilars that meets the requirements of the Federal Food, Drug, and Cosmetic Act (FD&C Act). The pathway includes showing that a biosimilar has the same high level of safety and effectiveness as the reference product. The FDA has approved several biosimilars, and more are in development.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS20363

Biosimilars Market: Market Drivers and Trends

The biosimilars market is expected to grow significantly in the next few years. The key drivers of this growth include the expiry of patents for biologic drugs, the increasing number of biosimilar products in development, and the growing awareness of biosimilars among patients and healthcare providers.

The number of biosimilar products in development has increased significantly in recent years. In Europe, there are currently more than 100 biosimilar products in clinical development, and this number is expected to grow in the coming years. In the United States, the FDA has approved several biosimilar products, and more are in development.

The increasing awareness of biosimilars among patients and healthcare providers is also driving growth in the market. Biosimilars are often seen as a more affordable alternative to biologic drugs, and they are also associated with a lower risk of adverse events.

The key trends in biosimilars technology are the increasing number of products in development, the growing awareness of biosimilars, and the increasing use of biosimilars in clinical practice.

The key drivers of the biosimilars market are the expiry of patents for biologic drugs, the increasing prevalence of chronic diseases, and the growing demand for biologic drugs.

The expiry of patents for biologic drugs is the primary driver of the biosimilars market. Biologic drugs are large, complex molecules that are difficult to replicate. As a result, when patents for these drugs expire, there are few companies that are able to produce biosimilars. The increasing prevalence of chronic diseases is also a driver of the biosimilars market. Chronic diseases, such as cancer and diabetes, require long-term treatment with biologic drugs. The growing demand for biologic drugs is also a driver of the biosimilars market. Biologic drugs are used to treat a variety of conditions, including cancer, autoimmune diseases, and inflammatory diseases.

Market Restraints and Challenges

The biosimilars market is still in its early stages of development, and there are a number of challenges that need to be addressed before it can reach its full potential. One of the key challenges is the lack of regulatory clarity around the world. In Europe, for example, biosimilars are regulated as generic medicines, while in the United States they are regulated as biological medicines. This difference in regulatory approach has created a complex and uncertain environment for biosimilar developers, which has made it difficult to bring products to market.

Another challenge facing the biosimilars market is the high cost of development. Biosimilar medicines are much more complex to develop than traditional small molecule drugs, and this complexity is reflected in the cost. It is estimated that it costs around $250 million to develop a biosimilar medicine, which is around 10 times more than the cost of developing a small molecule generic drug.

Biosimilars Market Report Findings

https://www.globalinsightservices.com/reports/biosimilars-market/

The insulin segment is likely to hold the major share of the market in 2023

Based on product, the market is classified into insulin and granulocyte colony-stimulating factor. The insulin segment has dominated the biosimilars market in 2023 and anticipated to dominate in the coming years. Also, granulocyte colony-stimulating factor segment is the fastest segment in the global biosimilars market.

The oncology segment is likely to hold the major share of the market in 2023

By application, the segment is classified into oncology, blood disorders, and growth hormonal deficiency. The oncology is the biggest contributor to the application segment and blood disorders segment is anticipated to be the fastest-growing in the market.

The North American region is likely to hold the major share of the market in 2023

Region-wise, the market is classified into North America, Europe, Asia-Pacific, and Rest of the world. The North American region has dominated the global biosimilars market. Expansion in these markets is mainly influenced by various factors, including the upcoming expiration of patents for biologic products and the introduction of new biosimilars. The increasing prevalence of chronic disorders, the arrival of new companies, and early market entry also contribute significantly to this growth.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS20363

Competitive Landscape

The biosimilars market report includes players such as Amgen (USA), Mylan (USA), Novartis (Switzerland), Sandoz (A subsidiary of Novartis) (Switzerland), Pfizer (USA), Biocon (India), Celltrion (South Korea), Samsung Bioepis (South Korea), Teva Pharmaceuticals (Israel), and Hospira (A subsidiary of Pfizer) (USA).

Biosimilars Market: Recent Developments
  • In November 2023, Sandoz has officially opened a new antibiotic production plant in Austria and a biosimilar development center in Germany. With a significant investment of EUR 25 million in Holzkirchen, the German site is set to become Sandoz’s primary analytical characterization center for biosimilars. As a major player in generic and biosimilar medicines, Sandoz aims to enhance sustainable development and the supply of essential medicines in Europe and beyond. This expansion aligns with the company’s ongoing commitment to meeting healthcare needs and ensuring a robust and reliable source of critical medications.
  • In July 2023, Sandoz is significantly increasing its focus on biosimilars with a $90 million investment in a new site in Slovenia. The company aims to boost the adoption of biosimilars globally, and this development center is a crucial part of that effort. The new facility is expected to play a key role in Sandoz’s biosimilar development, covering the entire process from drug substance to drug product. This strategic investment underlines Sandoz’s commitment to advancing biosimilar technologies and expanding its capabilities in Slovenia, where it plans to hire 200 employees.
  • In May 2023, Sandoz has entered a long-term partnership with Evotec for the development and manufacturing of biosimilars.
  • In May 2023, Sandoz and Just-Evotec Biologics have announced a multiyear collaboration to jointly develop and manufacture multiple biosimilar products. As part of this partnership, Sandoz will have access to Just-Evotec Biologics’ specialized platform for drug substance development and manufacturing technology. Leveraging these resources, Sandoz plans to expand its existing biosimilar pipeline from 15 to 24 products. Just-Evotec Biologics will receive an upfront payment in the double-digit-million range, followed by future payments totaling $640 million linked to successful development milestones. Additionally, the company will receive undisclosed payments based on progress in commercial manufacturing.

Biosimilars Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Biosimilars Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Biosimilars Market in terms of revenue ($Million) and volume (Units).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Biosimilars industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country, market analysis is also presented in this report.
  • The Biosimilars Market Study comprises an analysis of 23 countries. The research also encompasses a segment analysis of every country in terms of value (USD Million) throughout the study period.
  • Analytical depiction of the Biosimilars Market along with current trends and future estimations to depict imminent investment pockets. The overall Biosimilars industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Biosimilars Market are also analyzed.
  • The report also involves market strategy factors such as the ANSOFF Matrix, 4Ps Model, Demand-Supply Analysis, Competition Product Analysis, Recent Developments, Consumer Buying Interest, and Supply Chain Analysis among others.
Key Market Segments

By Product

  • Insulin
  • Granulocyte Colony-Stimulating Factor
  • Erythropoietin
  • Others

 By Application

  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa
Key Market Players
Read More

Biomaterials Market
February, 2024

New York, February 2024: According to a new research study by Global Insight Services (GIS), the Biomaterials Market is expected to grow rapidly over the next 10 years and it is expected to reach a CAGR 14.0% during the forecast period.

A biomaterial is a material engineered to interact with biological systems for a medical purpose – either a therapeutic or a diagnostic one. They can be derived either from nature, where they are called natural biomaterials, or they can be synthetic, in which case they are called artificial biomaterials. The first artificial biomaterials were made from polymers such as polyurethane and polyethylene. More recently, biomaterials have been made from a variety of different materials, including metals, ceramics, and even glass.

The main goal of using biomaterials is to replace or support damaged or diseased tissue or organ. Biomaterials can be used to replace parts of the body that have been lost due to trauma, disease, or congenital defects. They can also be used to support or enhance the function of a tissue or organ that is not working properly. There are many different types of biomaterials, and each has its own advantages and disadvantages. The most important properties of a biomaterial are its biocompatibility, mechanical strength, and durability. Biocompatibility is the ability of a material to safely interact with living tissue. Mechanical strength is the ability of a material to withstand the forces that are applied to it. Durability is the ability of a material to last for a long time without breaking it down.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS20230

Biomaterials Market: Market Drivers and Trends

The key trends in biomaterials technology are the development of new materials and the improvement of existing materials. New materials are being developed that are more biocompatible and can be used for a variety of applications. Improvements in existing materials are being made to make them more durable and to improve their performance.

The key drivers of the global biomaterials market are the increasing demand for biomaterials from the healthcare sector and the growing awareness about the benefits of biomaterials among the general population. The healthcare sector is the largest consumer of biomaterials, accounting for more than 50% of the total demand. This is attributed to the growing incidence of chronic diseases, the ageing population, and the increasing demand for minimally invasive procedures. Biomaterials are increasingly being used in a wide range of applications, such as orthopaedic, dental, and cardiovascular implants, and in tissue engineering. The growing awareness about the benefits of biomaterials along with its rising application is anticipated to drive the global biomaterials market growth.

Restraints & Challenges

The biomaterials market encounters hurdles like complicated regulations, expensive development, and strict approvals, slowing down product launches. Issues like limited compatibility, potential immune responses, and safety concerns further limit progress. The lack of standardized testing methods and ethical concerns about specific biomaterials can also impede market growth. Overcoming these challenges necessitates ongoing innovation, collaboration among stakeholders, and strict adherence to safety standards, ensuring responsible and continual progress in biomaterial technologies.

Biomaterials Market Report Findings

https://www.globalinsightservices.com/reports/biomaterials-market

The metallic segment is likely to hold the major share of the market in 2023

Based on type, the market is classified into Metallic, polymeric, ceramic, and natural. The metallic segment dominated the market in 2023 and anticipated to dominate in the coming years. Further, the polymeric segment has been growing the fastest in the global biomaterials market.

The cardiovascular segment is likely to hold the major share of the market in 2023

By application, the market is classified into cardiovascular, dental, orthopedic, and others. The cardiovascular segment has dominated the market in 2023 and further anticipated to be the fastest growing segment in the coming years. The growth is primarily is due to increase in chronic cardio diseases which fueling the segmental growth.

The North American region is likely to hold the major share of the market in 2023

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global market in 2023 and accounted for the largest share of more than xx% of the overall revenue. This is due to constant efforts by various public and private organizations like the National Science Foundation and the National Institute of Standards and Technology, there has been an increase in the use of biomaterials in biomedical applications. This has led to a growth in the adoption of biomaterials in the region. Additionally, favorable government policies and the presence of significant market players in the area have further boosted the market share.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS20230

Competitive Landscape

Some of the key players in the Biomaterials Market are BASF SE(DE), Stryker Corporation(US), Celanese Corporation(US), Corbion(NL), DSM(NL), Evonik Industries(DE), Carpenter Technology Corporation(US), Berkeley Advanced Biomaterials(US), Cam Bioceramics B.V.(NL), CoorsTek Inc.(US).

Biomaterials Market: Recent Developments
  • In July 2023, Biotechnology company Modern Meadow has partnered with global chemical firm BASF to revolutionize the material industry. Their collaboration combines Modern Meadow’s advanced biofabrication expertise with BASF’s Ultramid® Ccycled® material. Together, they aim to create a contemporary, sustainable, and animal-free material for the future. The result of this collaboration is Bio-VERA™, a groundbreaking substrate engineered by Modern Meadow. This material integrates BASF’s Ultramid® Ccycled® solution and utilizes Modern Meadow Bio-Alloy™ technology. By blending post-consumer waste with bio-renewable technologies, Bio-VERA™ offers a highly sustainable and luxurious material with exceptional performance capabilities.
  • In December 2022, Stryker has introduced Citrefix™, a suture anchor system for foot and ankle surgeries. This system utilizes Citregen™, an award-winning bioresorbable material that mimics the chemistry and structure of natural bone. Citrefix is a disposable system with a resorbable biomimetic anchor body made from Citregen. Citregen is an elastomeric material crafted from a citrate polymer, designed to imitate bone chemistry. Its controlled resorption capabilities aim to support tissue healing and promote healthy bone growth in orthopedic surgical applications. The sterile-packed set includes a cartridge with a preloaded implant and eyelet, a drill bit, a drill guide, and a pre-assembled inserter for the convenience of medical professionals.
  • In August 2021, Evonik has completed the acquisition of JeNaCell, a German biotech company, to enhance its biomaterials portfolio. JeNaCell specializes in biotechnologically derived cellulose used in medical applications for wounds, burns, and hydro-active skincare treatments. Evonik initially invested in JeNaCell in 2015 through its venture capital arm. Following this acquisition, JeNaCell’s products will be integrated into Evonik’s healthcare business, which is transitioning from a focus on nutrition and care to system solutions and an expanded technology platform for natural materials in medical technology. Evonik aims to increase the share of system solutions in its Nutrition & Care division from 20% to over 50% by 2030.
Biomaterials Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Biomaterials Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Biomaterials Market in terms of revenue ($Million) and volume (Units).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Biomaterials industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country, market analysis is also presented in this report.
  • The Biomaterials Market Study comprises an analysis of 23 countries. The research also encompasses a segment analysis of every country in terms of value (USD Million) throughout the study period.
  • Analytical depiction of the Biomaterials Market along with current trends and future estimations to depict imminent investment pockets. The overall Biomaterials industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Biomaterials Market are also analyzed.
  • The report also involves market strategy factors such as the ANSOFF Matrix, 4Ps Model, Demand-Supply Analysis, Competition Product Analysis, Recent Developments, Consumer Buying Interest, and Supply Chain Analysis among others.
Key Market Segments

By Product Type

  • Metallic
  • Polymeric
  • Ceramic
  • Natural

By Application

  • Cardiovascular
  • Dental
  • Orthopedic
  • Others

By Geography

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • South Korea
    • India
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa
Key Market Players
Read More

Genomics Market
January, 2024

New York, February 2024: According to a new research study by Global Insight Services (GIS), the Genomics Market is expected to grow rapidly over the next 10 years to reach a value of more than US$ 126.8 billion by 2033.

Genomics is the study of genes and their function. The market for genomics is expected to grow in the coming years as the technology becomes more affordable and accessible.

Products in the genomics market include sequencing, microarrays, and PCR. Sequencing is the most popular product, accounting for over half of the market share. Microarrays are used for gene expression and SNP analysis, while PCR is used for DNA amplification and sequencing.

The applications of genomics include drug discovery, disease diagnosis, and agricultural biotechnology. The drug discovery market is the largest application, accounting for over half of the market share. Genomics is also used in disease diagnosis, such as cancer, and in agricultural biotechnology, such as crop improvement.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS20110

Global Genomics Market: Market Drivers and Trends

Genomics is an agreement between a solar energy service provider and a customer wherein the service provider agrees The key trends in the genomics market are the increasing demand for personalized medicine and the increasing funding for genomics research.

Global Genomics Market: Market Restraints and Challenges

The key restraints in the market are the high cost of sequencing and the lack of skilled labor. The challenges in the market are the need for data storage and data management, the need for data interpretation and data analysis, and the need for data security.

Global Genomics Market Report Findings

https://www.globalinsightservices.com/reports/genomics-market/

The academic & research institutes segment is likely to hold the major share of the market in 2023                                            

Based on end user, the Genomics Market is segmented into hospitals & clinics, academic & research institutes, pharmaceutical & biotechnology companies, and others. The academic & research institutes segment is expected to dominate the market during the forecast period.

The epigenomics segment is likely to hold the major share of the market in 2023

By study type, the market is classified into functional genomics, biomarker discovery, pathway analysis, epigenomics, and others. The epigenomics segment dominated the market in 2023 in terms of revenue and is expected to dominate the market during the forecast period.

The sequencing segment is likely to hold the major share of the market in 2023

Based on technology, the Genomics Market is segmented into sequencing, PCR, flow cytometry, microarrays, and others. In 2023, the sequencing segment dominated the market in terms of revenue and is expected to be the same during the upcoming years.

The consumables & reagents segment is likely to hold the major share of the market in 2023

Based on Product & Services, the Genomics Market is segmented into consumables & reagents, services, and instruments, systems & software. The consumables & reagents segment is expected to dominate the market during the forecast period.

The drug discovery & development segment is likely to hold the major share of the market in 2023

Based on application, the Genomics Market is segmented into drug discovery & development, diagnostics, agriculture & animal research, and others. The drug discovery & development segment is expected to dominate the market during the forecast period.

The North America region is accounted for the majority of market share in 2023

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America has the biggest market share in terms of Genomics Market value followed by Asia Pacific. There are several factors contributing to the growth of the genomics market in the region. These include favorable initiatives by government and private bodies, as well as the increasing adoption of NGS and PCR-based diagnostics. Additionally, there has been a rise in the number of genomics startups and an increase in cancer research. Growing awareness of genomics services has also played a role, along with the presence of major players in the market, such as Illumina, Inc. (US), Thermo Fisher Scientific, Inc. (US), and Danaher Corporation (US).

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS20110

Competitive Landscape

The key players studied in the global Genomics Market are Oxford Nanopore Technologies (U.K)Danaher Corporation (U.S)Thermo Fisher Scientific Inc. (U.S)Eurofins Scientific (Luxembourg)F. Hoffmann-La Roche Ltd. (Switzerland)Illumina Inc. (U.S)Bio-Rad Laboratories (U.S)Agilent Technologies (U.S)Eppendorf (Germany)GE Healthcare Inc. (U.S), among others.

Global Genomics Market: Recent Developments
  • In March 2023, Illumina, Inc (US) has introduced Connected Insights, a new cloud-based platform that enables tertiary analysis of clinical next-generation sequencing data. This program will aid in genomic profiling (CGP) for advanced malignancies, whole-genome sequencing for uncommon disorders, and other sophisticated applications.
  • In February 2023, Eppendorf AG (Germany) expanded its production facilities in China by securing a contract to develop a new plant in Shanghai.
  • In February 2023, TrueMark STI Select Panel, a polymerase chain reaction (PCR) test developed for research purposes only, detects Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium.
  • In October 2022, Oxford Nanopore Technologies (UK) worked with 10x Genomics (US) to create a simplified approach for sequencing full-length transcripts in single reads using easily accessible Oxford Nanopore devices.
Global Genomics Market Report Coverage
  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Genomics Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Genomics Market in terms of revenue ($Million) and volume (Units).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Genomics industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country, market analysis is also presented in this report.
  • The Genomics Market Study comprises an analysis of 23 countries. The research also encompasses a segment analysis of every country in terms of value (USD Million) throughout the study period.
  • Analytical depiction of the Genomics Market along with current trends and future estimations to depict imminent investment pockets. The overall Genomics industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Genomics Market are also analyzed.
  • The report also involves market strategy factors such as the ANSOFF Matrix, 4Ps Model, Demand-Supply Analysis, Competition Product Analysis, Recent Developments, Consumer Buying Interest, and Supply Chain Analysis among others.
Global Genomics Market Segmentation
Market Segmentation:

By Products and Services

  • Consumables & Reagents
  • Services
  • Instruments, Systems & Software

By Technology

  • PCR
  • Sequencing
  • Microarray
  • Flow Cytometry
  • Others

By Application

  • Diagnostics
  • Drug Discovery and Development
  • Agriculture and Animal Research
  • Others

By Study Type

  • Functional Genomics
    • Transfection
    • Real-Time PCR
    • RNA Interference
    • SNP Analysis
    • Mutational Analysis
    • Microarray Analysis
  • Epigenomics
    • Bisulfite Sequence
    • High-Resolution Melt
    • Microarray Analysis
    • Chromatin Accessibility
  • Pathway Analysis
    • Bead-Based Analysis
    • Microarray Analysis
    • Real-Time PCR
    • Proteomics Tools
  • Biomarker Discovery
    • Mass Spectrometry
    • DNA Sequencing
    • Bioinformatics
    • Statistical Analysis
    • Real-Time PCR
  • Others

By End-Use

  • Research Centers and Academic Institutes
  • Hospitals & Clinics
  • Pharmaceutical & Biotechnology Companies
  • Others

By Region

  • North America
    • The U.S.
    •  Canada
    •  Mexico
  • Europe
    • The U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    •  Rest of Europe
  • The Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    •  Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  •  Rest of the World
    •  Latin America
    •  The Middle East
    •  Africa
Key Players
Read More

Genome Editing Market
January, 2024

Genome Editing Market to Reach US$ 29.85 Bn by 2033, driven by high occurrences of genetic disorders: Global Insight Services

New York, January 2024: According to a new research study by Global Insight Services (GIS), the global Genome Editing Market is expected to grow rapidly over the next 10 years to reach a value of more than US $ 29.85 Billion by 2033.

Genome Editing is a method for making specific changes to the DNA of a cell or organism. It can be used to add, remove or alter DNA in the genome. Human genome editing technologies can be used on somatic cells (non-heritable), germline cells (not for reproduction) and germline cells (for reproduction). In research, genome editing helps scientists study the effects of specific genetic changes and understand gene function. In medicine, it could allow doctors to correct disease-causing mutations.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20447/

Genome Editing Market: Key Trends and Drivers

High Occurrences of Genetic Disorders

More and more people are affected by genetic disorders worldwide. Research has helped scientists understand how genes cause disease better. New tests also allow more genetic conditions to be found. Many genetic problems have no good long-term treatments other than trying to manage symptoms. This shows the need for ways to fix the underlying genetic causes. New gene editing tools like CRISPR allow direct editing of DNA to correct disease-causing gene mutations. These precise, relatively inexpensive gene editing methods have sped up research on genetic diseases. There are also opportunities to develop new gene and cell therapies.

The increasing burden and improved knowledge of genetic disorders have made this area a top priority for more investment. Public, private and charity groups are all putting more funding into research and development. The investment will likely continue rising as science capabilities get better and gene editing opens up more treatment options for devastating genetic illnesses. Tackling these conditions is both a major medical need and a business opportunity.

Increase funding for genetic research

Increasing funding for genetic research is paramount to fueling the growth of the genome editing market. Adequate financial support not only facilitates the exploration of novel gene-editing technologies but also accelerates the development of groundbreaking treatments and therapies. Enhanced funding enables researchers to delve deeper into understanding genetic complexities, pushing the boundaries of innovation in genome editing. This influx of resources fosters collaborations, attracts top talent, and expedites the translation of scientific discoveries into tangible applications, ultimately driving the expansion of the genome editing market and offering promising avenues for advancements in personalized medicine and disease treatment.

Increased funding for genetic research, facilitated by initiatives such as the NHGRI budget and the U.S. Department of Energy’s Human Genome Program, plays a pivotal role in driving growth within the genome editing market. The NHGRI’s allocation of resources supports a dynamic intramural research program focused on genetic and genomic science and technology, alongside clinical research into the genetic origins of diseases. Moreover, NHGRI funding extends to education and training initiatives, nurturing the development of future genetic scientists. Similarly, the U.S. Department of Energy, through its Office of Biological and Environmental Research, channels resources into the Human Genome Program, further bolstering genetic research efforts. By amplifying financial support for these programs, the genome editing market receives a significant impetus, fostering innovation, collaboration, and the translation of genetic discoveries into transformative therapies and treatments.

Genome Editing Market: Restraints & Challenges

Lack of public awareness regarding genome editing technology

There are a few key things slowing the genome editing market. People worry about safely editing human genes that can be passed on to future generations. The rules around this are unclear or very strict in many countries. That creates barriers to use. There are also concerns about risks like errors and mistakes from editing. More safety data is needed. Genome Editing is still expensive and limited to advanced labs. Making it affordable and accessible everywhere is hard. The editing tools also need to get more accurate and efficient to minimize mistakes. Better communication to the public is important. There are also patent disputes and licensing issues that limit innovation incentives. Healthcare systems aren’t really set up yet to deliver genome editing therapies.

 Stringent government regulations

Stringent government regulations pose a significant challenge to the growth of the genome editing market. While genome editing technologies hold immense promise for revolutionizing healthcare, agriculture, and various industries, concerns about ethical implications, safety, and potential misuse have led governments to impose strict regulations. These regulations often entail lengthy approval processes, rigorous safety assessments, and compliance with ethical guidelines, which can significantly delay the development and commercialization of genome editing products and therapies. Moreover, divergent regulatory frameworks across different regions further compound the complexities faced by companies operating in the genome editing sector. As a result, the burden of navigating through regulatory hurdles adds uncertainty, increases costs, and slows down innovation, ultimately impeding the market’s growth during the forecast period.

Genome Editing Market Report Findings

https://www.globalinsightservices.com/reports/genome-editing-genome-engineering-market/

The CRISPR/Cas9 segment is likely to grow at a substantial CAGR during the forecast period.

By Technology, the Genome Editing market is segmented into Mega nucleases, (CRISPR)/Cas9, TALENs/MegaTALs, ZFN, and Others. Among them, the CRISPR/Cas9 segment dominated the market and had the significant revenue share in 2023. This method can accurately cut DNA strands and insert new genetic information, making it a very useful and popular tool. CRISPR/Cas9 is simple, highly efficient, precise, and can be used for many different applications like gene therapy, drug development, scientific research, agriculture, and animal breeding. The use of CRISPR for clinical applications to treat diseases like AIDS, cancer, and genetic disorders has been widely accepted, as seen by the growing number of ongoing clinical trials using this gene-editing technique. Hence, aforementioned factors will enhance the segment growth.

The ex-vivo segment is likely to hold a grow at a substantial CAGR during the forecast period.

By Delivery Method, the Genome Editing market is segmented into Ex-vivo, and In-vivo. Out of these the ex-vivo (outside the body) delivery method segment generated the significant revenue in 2023. This is because ex-vivo delivery offers advantages like more control over DNA modifications. The increasing number of clinical trials using genome editing tools has driven growth in the ex-vivo delivery segment, as this delivery method is being used more often. As a result of the successful Human Genome Project, almost 7,000 new human genetic diseases have been discovered. While ex-vivo gene editing-based gene therapies like CAR-T have had a significant impact, most patients with genetic diseases require in-vivo (inside the body) treatments. This requires precise editing tools and safe, targeted delivery systems that can be scaled up to help the entire patient population. This factor is contributing to the growth of the in-vivo segment.

The contract companies segment is likely to grow at a substantial CAGR during the forecast period.

By Mode, the Genome Editing market is segmented into Contract, and In-house. Among them, the contract segment was accounted for the significant revenue share. This is due to there is a high level of outsourcing activities in the gene editing field, driven by the lower costs and greater operational flexibility offered by outsourcing compared to in-house development. The contract segment is expected to grow further due to the increasing capabilities offered by key companies in this domain. In December 2022, a contract research organization (CRO) company named Crown Bioscience collaborated with ERS Genomics Limited. This gave Crown Bioscience access to ERS’s CRISPR/Cas9 patent portfolio and strengthened its market presence in the gene editing space. Such initiatives are expected to boost the outsourcing opportunities in the genome editing field and can positively impact the overall market growth.

The genetic engineering segment is likely to hold a significant market share and grow at a substantial CAGR during the forecast period.

By Applications, the Genome Editing market is segmented into Genetic Engineering, and Clinical Applications. The genetic engineering segment was accounted for the significant revenue share. This large share is due to the rapidly growing fields of gene therapy and stem cell therapy. The use of CRISPR gene editing in human induced pluripotent stem cells (hiPSCs) has important implications for stem cell research to treat various diseases. Cell line engineering involves modifying the genetic material in cells to produce or change an organism’s traits. It has several applications in biotechnology, gene therapy, and drug development. Cell line engineering is used in many research initiatives and has the potential to transform medicine. The market for cell line engineering is expected to grow rapidly in the near future because of advancements in technology and the increasing need for personalized medicine tailored to an individual’s genetics.

The biotechnology and pharmaceutical companies is likely to hold a significant market share and grow at a substantial CAGR during the forecast period.

By End-Use, the Genome Editing market is segmented into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations. Among these, the biotechnology and pharmaceutical companies segment was accounted for the significant market share in 2023. This is attributed to the growing number of research activities by these companies to develop new therapies. Major global pharmaceutical companies are also partnering with emerging companies to create new technologies. Increased research and development efforts for novel treatments are the main factors driving revenue growth in this segment.

Additionally, an increase in strategic partnerships and agreements between key players in the market is expected to fuel further market expansion. For example, in January 2022, CRISPR Therapeutics and Capsida Biotherapeutics formed a strategic agreement to create innovative gene therapies using CRISPR/Cas9 technology for treating various diseases. As part of the agreement, Capsida will provide its virus-based delivery technology, while CRISPR Therapeutics will contribute its expertise in genome editing. Thus, abovd=edmentioned factors will create new growth opportunities for the biotechnology and pharmaceutical companies, thereby boost the industry growth.

The North America region is estimated to exhibit the significant growth rate during the Genome Editing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World.  North America is expected to showcase a significant CAGR in the forecast period. This dominant position is due to the increasing investments being made in research and development of gene editing technologies in North America. The region is projected to maintain its lead over the forecast period because it is home to several major biotechnology and pharmaceutical companies that are working to develop genome editing technologies. Within North America, the United States held the largest market share for genome editing technology. This is due to increased government funding and support for scientific research and development in the U.S. The presence of major players such as Editas Pharmaceuticals, Thermo Fisher Scientific, and CRISPR Therapeutics in the region is also expected to drive further market expansion in North America.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20447/

Competitive Landscape

The key players in the market are CRISPR Therapeutics (Switzerland), Editas Medicine (United States), Intellia Therapeutics (United States), Sangamo Therapeutics (United States), Precision Biosciences (United States), Synthego (United States), Cellectis (France), Horizon Discovery Group (United Kingdom), GenScript Biotech Corporation (China), Bluebird Bio (United States), Integrated DNA Technologies, Inc., Beam Therapeutics, Thermo Fisher Scientific, and Caribou Biosciences, Inc., among others.

Recent Developments in the Genome Editing Market:

  • In December 2023, Tome Biosciences, a new gene editing startup, launched with $213 million in financing from investors including Andreessen Horowitz, Arch Venture Partners, and GV. Co-founded by Omar Abudayyeh and Jonathan Gootenberg from MIT’s McGovern Institute, Tome will focus on developing CRISPR-based therapies for monogenic liver diseases and autoimmune diseases.
  • In February 2022, Integrated DNA Technologies introduced Alt-R HDR Donor Blocks in February 2022, presenting an enhanced solution aimed at elevating homology-directed repair (HDR) rates. This innovation marks a valuable addition to IDT’s comprehensive array of Alt-R CRISPR genome editing solutions.
  • In February 2022, In the same month, Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. shared encouraging interim data from an ongoing Phase I clinical study involving their primary in vivo genome editing candidate, NTLA-2001 (Investigational Crispr Therapy For Transthyretin (Attr) Amyloidosis).

Genome Editing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Genome Editing Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Genome Editing Market in terms of revenue ($Million)
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Genome Editing industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country, market analysis is also presented in this report.
  • The Genome Editing Market Study comprises an analysis of 23 countries. The research also encompasses a segment analysis of every country in terms of value (USD Million) throughout the study period.
  • Analytical depiction of the Genome Editing Market along with current trends and future estimations to depict imminent investment pockets. The overall Genome Editing industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Genome Editing Market are also analyzed.
  • The report also involves market strategy factors such as the ANSOFF Matrix, 4Ps Model, Demand-Supply Analysis, Competition Product Analysis, Recent Developments, Consumer Buying Interest, and Supply Chain Analysis among others.

Global Genome Editing Market Segmentation

By Technology 

  • Meganucleases
  • (CRISPR)/Cas9
  • TALENs/MegaTALs
  • ZFN
  • Others

By Delivery Method

  • Ex-vivo
  • In-vivo

By Mode 

  • Contract
  • In-house

By End-Use

  • Biotechnology & Pharmaceutical Companies
  • Academic & Government Research Institutes
  • Contract Research Organizations

By Applications

  • Genetic Engineering
  • Clinical Applications

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa

Key Players

Read More

Sildenafil Drug Market
November, 2023

New York, November 2023: According to a new research study by Global Insight Services (GIS), the Sildenafil Drug Market is expected to grow rapidly over the next 10 years to reach a value of more than US$ 4.5 billion by 2032.

Sildenafil is a PDE5 inhibitor that is used to treat erectile dysfunction (ED) and pulmonary arterial hypertension (PAH). It improves blood flow to the penis, allowing it to attain and sustain an erection, making it an effective impotence therapy.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS26635

Global Sildenafil Drug Market: Market Drivers and Trends

Erectile dysfunction (ED) is becoming more common: Erectile dysfunction (ED) is becoming more common across the world. According to statistics, 30-40% of men have ED by the age of 40. The expanding senior population and age-related health conditions are adding to the patient pool. The large unmet demands of ED patients are projected to fuel sildenafil medication demand in the next years. With increased ED therapy awareness and acceptability, patient usage of sildenafil is anticipated to rise.

Patent expiration leads to the release of generics: The patent expiration of branded sildenafil medications such as Viagra has resulted in the release of generic equivalents by several pharmaceutical firms. The reduced cost of generics in comparison to branded counterparts is increasing their popularity. To gain market share, companies are concentrating on producing generic sildenafil formulations. The advent of generics has made ED therapy more accessible and inexpensive, propelling the sildenafil medication industry forward.

Global Sildenafil Drug Market: Market Restraints and Challenges

Side effects and safety concerns: Sildenafil use has been linked to headaches, flushing, vision abnormalities, back discomfort, and gastrointestinal difficulties. There have also been occasional reports of major side effects such as hearing and vision loss. Concerns about harmful effects restrict the widespread use of sildenafil medicines. This needs thorough monitoring and care during therapy. Providers frequently avoid providing sildenafil to patients who have specific medical issues, which impedes progress.

Social stigma connected with ED: The social stigma and humiliation associated with sexual illnesses such as erectile dysfunction sometimes deter people from seeking medical help. Many individuals are reluctant to discuss sexual issues with their doctors. The stigma reduces the number of patients who are diagnosed and treated with sildenafil. Efforts to raise knowledge and sensitize the public about ED will assist in alleviating this constraint.

Global Sildenafil Drug Market Report Findings

https://www.globalinsightservices.com/reports/sildenafil-drug-market/

The branded drugs segment is likely to hold the major share of the market in 2022

Based on drug type, the Sildenafil Drug is segmented into branded drugs, generic drugs, and over the counter drugs. The branded drugs segment is expected to dominate the market during the forecast period.

The erectile dysfunction segment is likely to hold the major share of the market in 2022

By indication, the market is classified into erectile dysfunction, pulmonary arterial hypertension, benign prostatic hyperplasia, and others. The erectile dysfunction segment dominated the market in 2022 in terms of revenue and is expected to dominate the market during the forecast period.

The hospital pharmacies segment is likely to hold the major share of the market in 2022

Based on distribution channel, the Sildenafil Drug is segmented into hospital pharmacies, retail pharmacies, online pharmacies, and others. In 2022, the hospital pharmacies segment dominated the market in terms of revenue and is expected to be the same during the upcoming years.

The tablets segment is likely to hold the major share of the market in 2022

Based on dosage form, the Sildenafil Drug is segmented into tablets, oral jellies, injections, and others. The tablets segment is expected to dominate the market during the forecast period.

The North America region is accounted for the majority of market share in 2022

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America has the biggest market share in terms of Sildenafil Drug value followed by Europe North America’s market development is attributable to high ED awareness, simple availability and access to ED medications, and the presence of key companies in the area. The European market for Sildenafil Drug Market is predicted to be the second largest. The expanding elderly population, increasing frequency of chronic conditions, and the introduction of new generic ED medications are driving market expansion in Europe. During the projected period, the Asia Pacific market is likely to be the fastest-growing market for Sildenafil Drug Market. The Asia Pacific market is booming due to an increasing patient population, increased healthcare spending, and an increase in online sales of ED medications.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS26635

Competitive Landscape

The key players studied in the global Sildenafil Drug Market are Pfizer, Teva Pharmaceuticals, Aurobindo Pharma , Alembic Pharmaceuticals , Torrent Pharmaceuticals , Lupin, Reddy’s Laboratories, Zydus Cadila, Amneal Pharmaceuticals, and Hetero among others.

Global Sildenafil Drug Market: Recent Developments

  • In October 2022, Hetero and Biophore formed a strategic alliance to launch Sildenafil tablets in the United States. The partnership paired Biophore’s R&D skills with Hetero’s global reach of more than 100 nations.
  • In January 2022, Sildenafil pills, a generic version of Viagra, received FDA approval, expanding the company’s generics range in the US.
  • In June 2021, Following FDA permission, Aurobindo Pharma introduced Sildenafil pills. In the US market, the medicine is believed to aid people suffering from erectile dysfunction.
  • In April 2021, Dr. Reddy has bought Eton Pharmaceuticals ‘EM-104, a novel oral suspension formulation of Sildenafil. The acquisition broadened Dr. Reddy’s product range in the male health sector in the United States.
  • In March 2020, Lupin announced the introduction of Sildenafil pills after getting FDA clearance. The product broadened the company’s portfolio in the generics market in the United States.
  • January 2020, Cipla purchased Exelan’s sildenafil products used to treat pulmonary arterial hypertension (PAH) in more than 15 countries. Cipla’s worldwide respiratory product portfolio was enhanced because of the purchase.

Global Sildenafil Drug Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Sildenafil Drug Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future global Sildenafil Drug Market potential from 2022 to 2032 in terms of revenue ($ Million), and Volume (Units).
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the global Sildenafil Drug Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Sildenafil Drug Market industry.

Global Sildenafil Drug Market Segmentation

By Drug Type

  • Branded Drugs
  • Generic Drugs
  • Over the Counter Drugs

By Indication

  • Erectile Dysfunction
  • Pulmonary Arterial Hypertension
  • Benign Prostatic Hyperplasia
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

By Dosage Form

  • Tablets
  • Oral Jellies
  • Injections
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Key Players

 

Read More

Visual Arts Therapy Market
November, 2023

New York, November 2023: According to a new research study by Global Insight Services (GIS), the Visual Arts Therapy Market is expected to grow rapidly over the next 10 years to reach a value of more than US$ 4.3 billion by 2032.

Drawing, painting, sculpture, and other art forms are used in visual arts therapy to promote physical, mental, and emotional well-being. It is utilized to treat a variety of mental health difficulties, cognitive impairments, and chronic health conditions by providing a nonverbal avenue for expression and communication.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS26634

Global Visual Arts Therapy Market: Market Drivers and Trends

Growing incidence of Mental Health problems: A key reason driving development in the visual arts therapy market is the growing incidence of mental health problems such as anxiety, depression, Post-traumatic Stress Disorder (PTSD), drug misuse, and trauma. The World Health Organization (WHO) estimates that around 1 billion individuals worldwide suffer from a mental condition. Visual arts therapy can assist people with various mental health issues to improve their symptoms and quality of life. The growing prevalence of mental diseases and the need for effective treatments are driving up demand for arts-based therapy.

Growing Geriatric Population: The world’s growing aging population creates considerable prospects for the visual arts therapeutic sector. Older persons are more vulnerable to age-related illnesses that impair cognitive functions, such as dementia, Alzheimer’s, and other neurodegenerative disorders. In older people, visual art approaches can increase brain activity, improve motor abilities, and improve mood and cognition. The aging population’s sensitivity to mental health decline is predicted to enhance the use of art treatments.

Global Visual Arts Therapy Market: Market Restraints and Challenges

The increased in maintenance costs & design limitations are likely to hinder the growth of the worldwide Visual Arts Many insurers continue to deny coverage for art therapy treatments, and out-of-pocket expenses remain high, restricting uptake. Certain private insurance plans only cover a portion of the therapist’s services if the therapist is an approved healthcare professional. Medicare likewise restricts reimbursement for creative art treatments. A key barrier influencing market potential is a lack of comprehensive coverage mixed with high therapeutic costs.

Lack of Trained Specialists: The visual arts therapy business is facing a serious supply-side restriction due to a lack of competent therapists to fulfill rising demand. Most nations have a scarcity of recognized graduate schools and supervised clinical training opportunities. Prospective students are often put off by the hard educational requirements and high expense of art therapy master’s degrees. The scarcity of qualified art therapists is a major impediment to industry expansion.

Global Visual Arts Therapy Market Report Findings

https://www.globalinsightservices.com/reports/visual-arts-therapy-market/

The photography segment is likely to hold the major share of the market in 2022

Based on type, it is segmented into painting, music, dance, drama, photography, and others. The photography segment had the highest revenue share in 2022 and is expected to continue to dominate the market over the period.

The PTSD patients segment is likely to hold the major share of the market in 2022

Based on application, it is bifurcated into cancer patients, dementia patients, PTSD patients, physical disabilities, mental health issues, substance abuse issues, and others. The PTSD patients segment has dominated the market in 2022 and expected to expand the fastest.

The rehab centers segment is likely to hold the major share of the market in 2022

Based on end user, it is segmented into hospitals, rehab centers, nursing homes, community centers, psychiatric facilities, counseling practices, and others. The rehab centers segment is expected to be the largest segment in the Visual Arts Therapy Market in 2022.

The North America region is accounted for the majority of market share in 2022

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. In 2022, the North America region Visual Arts Therapy Market had the highest revenue share followed by Europe. North America’s market development may be ascribed to the region’s high awareness levels, developed healthcare infrastructure, and advantageous reimbursement policies. Visual arts therapy is predicted to be the second-largest market in Europe. The increase is due to the region’s growing senior population and the increased use of art therapy in hospital settings. During the projection period, Asia Pacific is predicted to be the fastest-growing market for visual arts therapy. The increase is due to rising healthcare costs and the increasing use of expressive arts therapy in the region’s schools and community organizations.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS26634

Competitive Landscape

The key players studied in the global Visual Arts Therapy Market are NeurAbilities Healthcare , Promises Healthcare , Allied Health 2U, Sensational Kids., Laura Baker Services Association , Creative Clinical Consulting LLC , Luna Psychotherapy , Early Links , American Art Therapy Association , and Vlinder Expressive Arts Therapy Gold Coast among others.

Global Visual Arts Therapy Market: Recent Developments

  • In September 2023, The Graduate Art Therapy Program expanded its partnership with the Rubin Museum to provide free art therapy sessions to the public.
  • In July 2023, Driscoll Children’s Hospital, a pediatric tertiary care hospital, launched the first-ever art therapy program, allowing kids to express themselves in ways that words may not always be able to.
  • In July 2023, through poems and collages, students from the Dominican University of California’s MFA in Creative Writing and Ph.D. in Art Therapy departments collaborated. The two programs at the School of Liberal Arts and Education collaborated during the annual MFA Summer Residency, which was attended by 31 Dominican students.
  • In October 2022, Naropa University has introduced a new online bachelor’s degree program in art therapy. Students actively participate in contemplative research, personal art making, and artist identity development in addition to a comprehensive study of the therapeutic theories required preparing for a profession as an art therapist. A critical component of this cautious approach to the new internet medium.

Global Visual Arts Therapy Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Visual Arts Therapy Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future global Visual Arts Therapy Market potential from 2022 to 2032 in terms of revenue($ Million), and Volume(Units).
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the global Visual Arts Therapy Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Security Robots industry.

Global Visual Arts Therapy Market Segmentation

By Type

  • Painting
  • Music
  • Dance
  • Drama
  • Photography
  • Others

By Application

  • Cancer Patients
  • Dementia Patients
  • PTSD Patients
  • Physical Disabilities
  • Mental Health Issues
  • Substance Abuse Issues
  • Others

By End User

  • Hospitals
  • Rehab Centers
  • Nursing Homes
  • Community Centers
  • Psychiatric Facilities
  • Counseling Practices
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Key Players

 

Read More

Animal Model Market
September, 2023

New York, September 2023: According to a new research study by Global Insight Services (GIS), the Animal Model Market is expected to grow rapidly over the next 10 years to reach a value of more than US$ 3.6 billion by 2032.

Non-human organisms, usually animals, are employed in scientific research to examine biological processes, discover disease causes, create new therapies, and gain knowledge about human health and physiology. Animal models are important in many domains, including medicine, pharmacology, genetics, and toxicity. They enable researchers to comprehend complicated biological systems, test ideas, and make forecasts before proceeding to human trials.

Request Sample Pages of this Research Report

https://www.globalinsightservices.com/request-sample/GIS25738/

Animal Model Market: Market Drivers and Trends

Rise in the usage of the animal models in virology is driving the market expansion. Animal models, including mice, rats, guinea pigs, and nonhuman primates, are critical in investigating the pathophysiology, transmission, and potential therapies for a variety of viral infections and infectious illnesses. These models provide a crucial platform for researchers to better understand the intricate mechanisms of viral replication, host immune responses, and disease development. Animal models have been found to be invaluable tools in virology research, enabling scientists to simulate human illnesses and evaluate the efficiency of antiviral medicines and vaccinations. In the instance of the COVID-19 pandemic, for example, animal models were critical in comprehending the SARS-CoV-2 virus and assessing prospective treatment strategies. Researchers to explore viral entrance, replicating, and dissemination, as well as to evaluate vaccine candidates and antiviral medicines utilized animal models. These studies shed light on the virus’s behaviour and aided in the development of efficient preventative and treatment measures.

Additionally, increase in the CRISPR technology is going to boost the market growth in the coming years. CRISPR allows scientists to modify individual genes in animals with remarkable accuracy, resulting in more precise disease models. Scientists can imitate the genetic abnormalities found in patients by introducing particular mutations linked with human illnesses into animal genomes, allowing for a deeper understanding of disease processes and the evaluation of prospective therapeutic approaches. CRISPR, for example, has been used to investigate cancer, based on a 2022 report by the National Library of Medicine, since the approach offers various new methods to mimic the illness. This involves the creation of pre-clinical cancer models in which CRISPR is used to produce mutations found in human cancer. As a result, rare mutations may be examined in a physiologically appropriate context, and CRISPR technology has sped up the development of these models. CRISPR technology developers Emmanuelle Charpentier and Jennifer Doudna were awarded the Nobel Prize in 2020. These drivers are likely to propel market expansion.

Animal Model Market: Market Restraints and Challenges

To ensure the ethical and appropriate application of animals in scientific research, strict regulatory criteria for animal model utilization are in place. To protect animal welfare, a structure of strong regulations and rigid norms exists. These restrictions are extensive and differ from one country to the next. Typically, regulatory requirements demand that researchers establish the scientific need and possible benefits of utilizing animal models. Institutional animal care and use committees (IACUCs) or equivalent regulatory agencies conduct ethical reviews of research proposals involving animal testing. These committees evaluate the proposed studies’ rationale, design, and welfare issues. Such severe and changeable laws may impede the employing of animal models in scientific research, stifling corporate growth.

Animal Model Market Report Findings

https://www.globalinsightservices.com/reports/animal-model-market/

The mice segment is likely to hold the major share of the market in 2022

Based on animal type, the Animal Model Market is segmented into rat, mice, guinea pigs, rabbits, and others. The mice segment is expected to dominate the market during the forecast period. Increased investment and technical improvement in mouse model technologies are expected to fuel market expansion. Furthermore, the growing implications of mouse clinical trials for further predicted results, as well as the increasing desire for personalized therapy, are driving up demand for mice models. For example, in March 2023, National Institutes of Health researchers investigated an improved genetic animal model of Down syndrome. The unique mouse model provided prospective treatment possibilities for the illness.

The cancer segment is likely to hold the major share of the market in 2022

By application, the market is classified into cancer, immunological disease, infectious disease, and others. The cancer segment dominated the market in 2022 in terms of revenue and is expected to dominate the market during the forecast period. The market is expected to rise due to factors such as the translational importance of animal models in cancer research, the growing trend of precision oncology, and developments in tumor modeling methodologies. These models are used to assess the safety and effectiveness of anti-cancer treatments in clinical trials and preclinical testing. Furthermore, animal models assist researchers in testing the therapeutic index, bioavailability, and pharmacokinetic features of anti-cancer medicines prior to moving on with human clinical trials. Charles River Laboratories and Creative Biolabs are two firms that provide models for cancer research and treatment development.

The pharma and biotech companies segment is likely to hold the major share of the market in 2022

Based on end-user, the Animal Model Market is segmented into pharmaceutical & biotechnology companies, academic research institute, and contract research organization. In 2022, the pharma and biotech companies segment dominated the market in terms of revenue and is expected to be the same during the upcoming years. Companies’ increased attempts to create innovative treatment regimens are expected to boost the segment’s growth. Additionally, pharmaceutical firms’ increased medication discovery and development operations are contributing to category expansion. Furthermore, a large number of research-driven pharmaceutical businesses and their numerous activities are expected to boost market expansion.

The North America region is accounted for the majority of market share in 2022

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America has the biggest market share in terms of Animal Model Market value followed by Asia Pacific. The presence of significant companies and many strategic efforts by them are attributed to the region’s growth. Furthermore, expanding biomedical research and clinical trial spending are driving regional market expansion. Furthermore, advances in genetic modification and the increasing use of animal-based models for drug profiling and characterization are projected to open up new opportunities for market expansion.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS25738/

Competitive Landscape

The key players studied in the Animal Model Market are The Jackson Laboratory, Charles River Laboratories, Crown Bioscience Inc., Janvier Labs, Hera Biolabs, Taconic Biosciences, Genoway S.A., Inotiv, Inc., Ozgene Pty Ltd., and BioSpherix, Ltd. among others.

Animal Model Market: Recent Developments

  • In January 2023, Charles River Laboratories has announced the addition of two additional NCG mice strains to their triple-immunodeficient mouse model portfolio, which are best suited for investigations in cancer, immunology, and infectious diseases.
  • In November 2022, Charles River Laboratories stated that it has inked a deal with Hera BioLabs to breed, distribute, market, and sell the SRG rat for use by the global preclinical research community.
  • In September 2022, Genoway S.A. and Sigma-Aldrich Co LLC established a new framework for their 2018 CRISPR/Cas9 strategic collaboration. GenOway will continue to spearhead the commercialization of Sigma-Aldrich’s CRISPR patent property in rodent species.
  • In June 2021, Genoway S.A. has announced a non-exclusive licence arrangement with ERS Genomics Limited. The arrangement gives GenOway access to ERS Genomics’ CRISPR/Cas9 patent portfolio in the past and in the future.
  • In December 2020, Genoway S.A. has established a strategic collaboration with Cyagen to commercialise high-quality preclinical humanised immune checkpoint and immunodeficient BRGSF mice models to charity and for-profit organisations in Asia-Pacific beginning in 2020.

Animal Model Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Animal Model Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future global Animal Model Market potential from 2022 to 2032 in terms of revenue ($ Million) and Volume (Units).
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the global Animal Model Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global Animal Model Market industry.

Animal Model Market Segmentation

By Animal Type

  • Rat
  • Mice
  • Guinea pigs
  • Rabbits
  • Others

By Application

  • Cancer
  • Immunological Disease
  • Infectious Disease
  • Others

By End-User

  • Pharmaceutical & Biotechnology Companies
  • Academic Research Institute
  • Contract Research Organization

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • The U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Netherlands
    • Sweden
    • Switzerland
    • Denmark
    • Finland
    • Russia
    • Rest of Europe
  • The Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Taiwan
    • Malaysia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • The Middle East
    • Africa

Key Players

Read More

Peptide Synthesis Market
July, 2023

Peptide Synthesis Market to Reach US$ 4.2 bn by 2032, driven by steep rise in the adoption of peptides in the pharmaceutical and consumer healthcare industries: Global Insight Services

New York, July 2023: According to a new research study by Global Insight Services (GIS), the global Peptide Synthesis Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 4.2 bn by 2032.

Peptides are a unique class of highly active and specific pharmaceutical compounds, molecularly poised between small molecules and proteins, yet biochemically and therapeutically diverse from both. The advantages of peptides, such as relative ease of synthesis, ready availability, and low toxicity, increased their applications in the pharmaceutical, nutritional, and cosmetic industries, resulting in high demand for rapid advancements in the technologies to enhance their synthesis..

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20547/

Peptide Synthesis Market: Key Trends and Drivers

The market for peptides has experienced significant growth due to their widespread adoption in the pharmaceutical and consumer healthcare industries. Peptides are being increasingly utilized in the treatment of various lifestyle disorders, including cancers, diabetes, and obesity. The rising prevalence of these metabolic and lifestyle disorders has created a favorable environment for the application of peptide therapeutics in the fields of oncology and metabolic disorders. According to data published by the International Diabetes Federation in 2021, there were 537 million adults (20-79 years) globally living with diabetes, which accounted for approximately 1 in 10 individuals. Additionally, 541 million adults were identified as having Impaired Glucose Tolerance (IGT), putting them at a high risk of developing type 2 diabetes. Peptide therapies like Glucagon-like peptide-1amide have gained popularity in pancreatic therapy as they stimulate insulin secretion postprandially. Consequently, the increasing number of diabetic patients is expected to drive the demand for peptide drugs and contribute to market growth in the foreseeable future.

The peptide synthesis market has also witnessed significant expansion due to increased research activities, novel product approvals, and enhanced funding for research and development. Furthermore, advancements in peptide synthesizers have provided additional advantages, further fueling market growth. An example of recent progress in this field is ISSAR Pharma’s announcement in April 2021 regarding the licensing of their peptide-based New Chemical Entities (NCEs), which have reached the pre-investigational new drug (IND) filing stage and obtained a United States patent. These notable developments in peptide drugs are expected to create a surge in market demand and drive the overall growth of the industry.

Peptide Synthesis Market: Restraints & Challenges

The peptide synthesis market faces several restraints that can hinder its growth and development. Firstly, the high cost of peptide synthesis, including equipment, reagents, and skilled labor, presents a significant barrier for entry and limits the accessibility of peptide synthesis technologies. Additionally, the complexity and time-consuming nature of peptide synthesis processes pose challenges in terms of scalability and efficient production, limiting the ability to meet the growing demand for peptides in various fields such as pharmaceuticals and biotechnology. Furthermore, regulatory constraints and safety concerns related to the use of peptides, especially in therapeutic applications, impose strict guidelines and approval processes, leading to delays and additional costs. These restraints collectively impede the expansion and advancement of the peptide synthesis market.

Peptide Synthesis Market Report Findings

https://www.globalinsightservices.com/reports/peptide-synthesis-market/

The equipment segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

Based on the product, the global market for peptide synthesis is divided into equipment, reagents & consumables, and others. Out of these equipment segment accounted for substantial market share in the year 2022.. The development of innovative peptide synthesis equipment has greatly contributed to the rapid growth of this segment in the global market. For instance, in February 2017, researchers at MIT introduced a new piece of equipment that enables faster peptide synthesis compared to existing options. This automated machine can create links between amino acids in just approximately 37 seconds, allowing for the production of large quantities of customized peptides in a shorter timeframe. On the other hand, reagents and consumables have generated the highest revenue among other peptide synthesis products. This is mainly due to their regular use in peptide synthesis protocols. Furthermore, recent advancements in peptide coupling reagents are expected to further drive market growth in the upcoming years.

The Liquid Phase Peptide Synthesis (LPPS) segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

By technology, the industry is bifurcated into Solid Phase Peptide Synthesis (SPPS), Liquid Phase Peptide Synthesis (LPPS), and Hybrid & Recombinant Technology. Liquid-phase peptide synthesis has dominated the global market throughout the projected period, while solid-phase peptide synthesis has exhibited the fastest growth from 2022 to 2032. The integration of automation and advancements in both liquid and solid-phase peptide synthesis has significantly contributed to cost reduction in peptide synthesis, driving its adoption worldwide and leading to increased global revenue. Traditional studies suggest that solid-phase peptide synthesis is a suitable approach for GMP manufacturing and API process development, particularly for cost-effective synthesis of long peptide sequences (more than 10 amino acids) in smaller volumes. However, purification costs during solid-phase peptide synthesis can increase manufacturing costs at any production scale. On the other hand, liquid-phase peptide synthesis is commonly used for developing shorter peptide sequences and larger volumes. Hybrid approaches are employed for synthesizing long sequences in large volumes.

The therapeutics segment is likely to hold a dominant Peptide Synthesis Market share and grow at a substantial CAGR during the forecast period.

Based on application, the industry is categorized into therapeutics, diagnosis, and research. The therapeutics segment, which includes various medical areas such as cancer, metabolic disorders, cardiovascular disorders, respiratory conditions, gastrointestinal disorders, infectious diseases, pain management, dermatology, central nervous system disorders, renal conditions, and others, was the leading revenue generator in the year 2022. This segment is anticipated to maintain its dominance throughout the forecast period.

On the other hand, the diagnosis segment is projected to experience the fastest growth from 2019 to 2026. The use of synthesized peptides in cancer treatment has significantly contributed to the revenue generated by the therapeutics segment, making it a major contributor in this market. Furthermore, within the therapeutics segment, the metabolic disorders segment is expected to exhibit the highest growth rate over the forecast period. This growth can be attributed to the presence of a robust pipeline and a substantial number of peptide candidates for treating type II diabetes. The discovery of novel peptides that play a crucial role in metabolic regulation is anticipated to provide valuable insights for the development of effective therapeutic approaches.

The Pharmaceutical & Biotechnology Companies segment is anticipated to hold a majority of the Peptide Synthesis Market size throughout the study period.

Based on end-user, the Peptide Synthesis market is divided into Pharmaceutical & Biotechnology Companies, Contract Development and Manufacturing Organization (CDMO), and Academic and Research Institutes. Among these, pharmaceutical and biotechnology companies are accounted for significant market share in 2022. This is owing to peptide therapies are gaining popularity in the pharmaceutical and biotechnology industries due to their cost-effectiveness, efficiency, and lower toxicity. The market for peptide synthesis is being driven by rapid advancements in peptide synthesizers and a robust pipeline of peptide therapeutics. In a 2022 article titled “Advances in oral peptide drug nanoparticles for diabetes mellitus treatment” published in Science Direct, it was highlighted that oral administration of peptide medications holds promise for treating diabetes mellitus. This approach is considered advantageous over traditional parenteral administration methods due to its simplicity and high patient compliance.

The growth of the market is further fueled by product launches, mergers, acquisitions, and the presence of competitors. An example of this is the world’s first “Peptide In A Pill” launched by Novo Nordisk India in January 2022. The peptide, Semaglutide, belongs to the GLP-1 receptor analog (GLP-1 RA) drug class and is used for managing type 2 diabetes. These developments are anticipated to drive the expansion of the pharmaceutical and biotechnology end-user segment in the peptide synthesis market.

The North America region is estimated to exhibit the highest growth rate during the Peptide Synthesis Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is projected to maintain its dominant position in the peptide synthesis market throughout the forecast period. This dominance can be attributed to the presence of advanced healthcare infrastructure and substantial investments by key players in North America. These investments aim to develop new peptide synthesis technologies, further fueling market expansion. For instance, in 2020, the United States Food and Drug Administration (US FDA) approved Imcivree (setmelanotide), a peptide derived from pro-opiomelanocortin, for chronic weight management in patients aged six years and older with obesity caused by rare genetic conditions. The US FDA’s accelerated drug approval initiative also plays a significant role in driving market growth in the region. These factors collectively contribute to North America’s outstanding market share in the global peptide synthesis market.

Moreover, increasing prevalence of obesity caused by sedentary lifestyles, poor dietary habits, and lack of physical activity, leading to various chronic diseases like diabetes in the United States. Effective treatment options are necessary to address these health concerns. For example, according to the International Diabetic Federation’s 2021 report, the North America Caribbean (NAC) region had an estimated 51 million adults aged 20-29 years living with diabetes, representing a regional prevalence of 14.6%. Additionally, this region has the second highest number of children and adolescents with type 1 diabetes, reaching 193,000 cases. The high prevalence of diabetes is expected to persist, resulting in a higher demand for peptide therapeutics and driving market growth in this region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20547/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Peptide Synthesis market include Bachem Holding AG, Thermo Fisher Scientific, Merck KGaA, GenScript Biotech Corporation, Kaneka Corporation, Biotage AB, Syngene International Ltd. , Mesa Laboratories inc. , CEM Corporation and ProteoGenix, among others.

Recent Developments in the Peptide Synthesis Market:

  • In June 2022, Evonik launched a new peptide to boost the productivity of cell-culture-based biopharmaceuticals. cQrex AC is a chemically defined and highly soluble source of L-cystine that enables a sufficient supply of this key amino acid to cells.
  • In May 2022, the United States Food and Drug Administration approved Mounjaro (tirzepatide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro is a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.

Peptide Synthesis Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Peptide Synthesis Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Peptide Synthesis market in terms of revenue ($Million)
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Peptide Synthesis Market industry.
  • A thorough analysis of market trends and restraints is provided
  • By region as well as country market analysis is also presented in this report
  • Analytical depiction of the Peptide Synthesis Market along with the current trends and future estimations to depict imminent investment pockets. The overall Peptide Synthesis Market Industry opportunity is examined by understanding profitable trends to gain a stronger foothold
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Peptide Synthesis Market are also analyzed.

Global Peptide Synthesis Market Segmentation

By Product

  • Equipment
  • Reagents & Consumables
  • Others

By Technology

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid & Recombinant Technology

By Application

  • Therapeutics
  • Diagnosis
  • Research

By End-user

  • Pharmaceutical & Biotechnology Companies
  • Contract Development & Manufacturing Organization/Contract Research Organization
  • Academic & Research Institutes

By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Bachem Holding AG
  • Thermo Fisher Scientific
  • Merck KGaA
  • GenScript Biotech Corporation
  • Kaneka Corporation
  • Biotage AB
  • Syngene International Ltd.
  • Mesa Laboratories inc.
  • CEM Corporation
  • ProteoGenix

 

Read More

Hormone Replacement Therapy Market
July, 2023

Hormone Replacement Therapy Market to Reach US$ 36.4 bn by 2032, driven by the rising incidence of target diseases and the availability of long-acting hGH products: Global Insight Services

New York, July  2023: According to a new research study by Global Insight Services (GIS), the global Hormone Replacement Therapy Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 36.4 bn by 2032.

hormone replacement therapy (HRT) is a treatment technique for replacing and/or replenishing hormones in the human body, which are at inadequate levels than those required for the normal physiology of the human body. The most prominent application of HRT is in the treatment of symptom alleviation of menopause.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS21882

Hormone Replacement Therapy Market: Key Trends and Drivers

One significant growth driver for the Hormone Replacement Therapy (HRT) market is the increasing awareness and acceptance of hormone replacement therapies for managing symptoms associated with menopause. As more women become educated about the benefits of HRT in alleviating hot flashes, night sweats, vaginal dryness, and other menopausal symptoms, the demand for these therapies is expected to rise. Moreover, with advancements in medical research and technology, the development of innovative and more targeted hormone therapies has become possible, catering to individual patient needs and preferences. This expanding range of treatment options, coupled with a growing aging population worldwide, is anticipated to fuel the growth of the HRT market in the coming years.

Hormone Replacement Therapy Market: Restraints & Challenges

One of the key restraints in the Hormone Replacement Therapy (HRT) market is the potential risk associated with long-term use of hormone replacement products. While HRT can provide relief from menopausal symptoms and other hormonal imbalances, studies have suggested an increased risk of certain health conditions, such as cardiovascular diseases and certain types of cancer, with prolonged use of HRT. These safety concerns have led to cautious prescribing practices and decreased patient acceptance, limiting the growth potential of the HRT market. Additionally, the availability of alternative therapies and the preference for non-hormonal treatment options further restraining the market growth.

Hormone Replacement Therapy Market Report Findings

https://www.globalinsightservices.com/reports/hormone-replacement-therapy-market/

The estrogen and progesterone replacement therapy segment is anticipated to hold a majority of the Hormone Replacement Therapy Market size throughout the study period.

Based on Therapy Type, it is analyzed across Estrogen Hormone Replacement Therapy, Human Growth Hormone Replacement Therapy, Thyroid Hormone Replacement Therapy, Testosterone Hormone Replacement Therapy, and Progestogen Hormone Replacement Therapy. Among these, the estrogen and progesterone replacement therapy segment emerged as the dominant market leader in the Hormone Replacement Therapy industry. This significant market share can be attributed to the rising demand for hormone replacement therapies among individuals experiencing hormonal imbalances or undergoing menopause. According to the American Congress of Obstetricians and Gynecologists, around 6,000 women reach menopause daily in the U.S. Estrogen and progesterone replacement therapies are widely used to alleviate symptoms and promote overall well-being, thereby driving the growth of this particular segment in the Hormone Replacement Therapy market.

Moreover, advancements in Hormone Replacement Therapy technologies and the availability of innovative delivery systems have further propelled the adoption of estrogen and progesterone replacement therapy. As the aging population continues to expand globally and individuals seek ways to manage hormonal imbalances and associated symptoms, the estrogen and progesterone replacement therapy segment is expected to maintain its strong market position. The Hormone Replacement Therapy market will continue to witness significant growth, driven by the increasing demand for hormone replacement products and ongoing research to develop novel peptides that offer enhanced efficacy and improved patient outcomes.

The parenteral segment is likely to hold a dominant Hormone Replacement Therapy Market share and grow at a substantial CAGR during the forecast period.

Based on route of administration, it is categorized into parenteral, oral, and transdermal. During the projected period, the parenteral segment is anticipated to experience significant growth. This growth can be attributed to advancements in drug delivery methods, particularly through pen-based drug delivery systems. These systems are expected to enhance patient compliance and simplify administration, thus driving the expansion of this segment. Some popular pen-based products include the Genotropin Mixer Pen, Norditropin FlexPro Pen, and Humatrope HumatroPen.

Additionally, the introduction of a new long-acting growth hormone injection is predicted to further fuel the growth of this segment. For example, in January 2022, Pfizer, Inc. and OPKO Health, Inc. obtained approval from the Ministry of Health, Labour and Welfare in Japan to market NGENLA, a next-generation long-acting growth hormone injection for treating growth hormone disorders. This product offers the advantage of a once-a-week dosage regimen, contributing to its potential impact on segment growth.

The hypothyroidism Companies segment is anticipated to hold a majority of the Hormone Replacement Therapy Market size throughout the study period.

On the basis of Indication, it is segmented into Hypothyroidism, Menopause, Male Hypogonadism, Growth Hormone Deficiency, and Others. In 2022, the the hypoparathyroidism segment is anticipated to experience substantial growth in the forecast period, driven by the development of novel treatments and the introduction of new products. For instance, in September 2020, Ascendis Pharma A/S presented its TransCon technologies at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting. The company also disclosed the top-line results of the phase 2 clinical trial for TransCon PTH at the same event. Currently, the drug is undergoing phase 3 clinical trials. Upon approval and subsequent launch, this product will offer additional options for parathyroid hormone replacement therapy

On the other hand, menopause segment emerged as the dominant force in the market, capturing a share. This can be attributed to the rising number of women experiencing menopause. According to the UN’s 2020 global estimates, there were 958 million women aged 50 and above, and this number is projected to reach 1.65 billion by 2050. As a result, a significant population of women is expected to spend a considerable portion of their lives after menopause in the future. However, the age of menopause can vary due to various factors, including natural factors such as habitat and genetics, which influence the timing of menopause for individuals.

The North America region is estimated to exhibit the highest growth rate during the Hormone Replacement Therapy Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America is projected to maintain its dominant position in the Hormone Replacement Therapy market throughout the forecast period. This region is expected to experience substantial growth throughout the forecast period. The significant market share can be attributed to several factors, including major product launches, collaborative agreements among manufacturers, and favorable reimbursement policies. An example of such a success is the approval of Sogroya (somapacitan-beco), a hormone replacement therapy product developed by Novo Nordisk A/S, by the U.S. FDA in August 2020. This particular product is administered once weekly via the subcutaneous route and is targeted towards adults diagnosed with growth hormone deficiency. The region’s strong healthcare infrastructure, increasing geriatric population, rising prevalence of hormonal disorders, and extensive research and development activities contribute to its leadership position. Additionally, favorable reimbursement policies, high healthcare expenditure, and robust pharmaceutical industry further propel the growth of the HRT market in North America, attracting both domestic and international players to invest in this lucrative market segment..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS21882/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Hormone Replacement Therapy market include AbbVie (U.S.), Allergan plc (U.S.), Amgen (U.S.), Bayer AG (Germany), Belmar Pharma Solutions (U.S.), Endo International plc (Ireland), Merck KGaA (Germany), Mithra Pharmaceuticals (Belgium), Novo Nordisk A/S (Denmark), and Pfizer Inc. (U.S.)., among others.

Recent Developments in the Hormone Replacement Therapy Market:

  • In February 2023, Korea’s Ministry of Food and Drug Safety approved Pfizer’s NGENLA for the treatment of growth hormone deficiency.
  • In June 2022, Halozyme Therapeutics, Inc. announced the commercial launch of TLANDO (testosterone undecanoate), an oral treatment indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone.
  • In February 2022, Pfizer Inc. and OPKO Health, Inc. announced that the European Commission has granted marketing authorization for the next-generation long-acting recombinant human growth hormone NGENLA, a once-weekly injection to treat children and adolescents from 3 years of age with growth disturbance due to insufficient secretion of growth hormone.
  • In January 2022, Pfizer, Inc. and OPKO Health, Inc. received approval from the Ministry of Health, Labour and Welfare, Japan, for the commercialization of NGENLA to treat growth hormone disorder. This product is the next-generation long-acting growth hormone injection, with a treatment frequency of a once-a-week dosage.
  • In November 2021, I-MAB Biopharma Co., Ltd. entered into a collaboration with Jumpcan Pharmaceutical Group for the development & commercialization of eftansomatropin alfa (TJ101) in China. TJ101 is a long-acting recombinant human growth hormone, which is currently under phase 3 clinical trial for the treatment of pediatric growth hormone deficiency. This collaboration is expected to strengthen its position in the hormone replacement therapy market.
  • In September 2020, Ascendis Pharma A/S showcased the TransCon technologies at the American Society for Bone and Mineral Research (ASBMR) 2020 Annual Meeting. It also published the top-line results of the phase 2 clinical trial for TransCon PTH at the annual meeting. The drug is currently in phase 3 clinical trials. The approval and subsequent launch of this product will provide more options available for parathyroid hormone replacemen
  • In August 2020, U.S. FDA approved Sogroya (somapacitan-beco) a HGH replacement therapy product developed by Novo Nordisk A/S. This product is administered once a weekly through subcutaneous route in adults diagnosed with growth hormone deficiency.

Hormone Replacement Therapy Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Hormone Replacement Therapy Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Hormone Replacement Therapy market in terms of revenue ($Million)
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Hormone Replacement Therapy Market industry.
  • A thorough analysis of market trends and restraints is provided
  • By region as well as country market analysis is also presented in this report
  • Analytical depiction of the Hormone Replacement Therapy Market along with the current trends and future estimations to depict imminent investment pockets. The overall Hormone Replacement Therapy Market Industry opportunity is examined by understanding profitable trends to gain a stronger foothold
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Hormone Replacement Therapy Market are also analyzed.

Global Hormone Replacement Therapy Market Segmentation

By Therapy Type

  • Estrogen Hormone Replacement Therapy
  • Human Growth Hormone Replacement Therapy
  • Thyroid Hormone Replacement Therapy
  • Testosterone Hormone Replacement Therapy
  • Progestogen Hormone Replacement Therapy

By Route of Administration

  • Oral
  • Parenteral
  • Transdermal

By Indication

  • Menopause
  • Hypothyroidism
  • Male Hypogonadism
  • Growth Hormone Deficiency
  • Others

By Region

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • The UK
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Singapore
    • Indonesia
    • Rest of Asia-Pacific
  • Rest of the World
    • Latin America
    • Middle East
    • Africa

Key Players

Read More

Vaccine Market
July, 2023

Vaccine Market to Reach US$ 128.6 Bn by 2032, driven by   newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe: Global Insight Services

New York, June 2023: According to a new research study by Global Insight Services (GIS), the global Vaccine Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $128.6 Billion by 2032.

A vaccine is a biological which is used to boost the person’s immune system and help to provide immunization against chronic diseases. The suspension consists of either weakened or killed forms of disease-causing microorganisms that enhance immunity without causing diseases. The vaccine provides active immunity against a specific harmful agent such as diseases caused by a certain pathogen, injection, bacteria, virus, or parasites. By stimulating the immune system to attack the agent and eliminating these agents and increasing the life of adults and elderly individuals. After stimulation by a vaccine, B lymphocytes remain sensitized and ready to respond to the agent whenever it enters the body next time.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10524

Vaccine Market: Key Trends and Drivers

The expanding availability of preventive as well as therapeutic vaccines for range of diseases will boost the market expansion. Furthermore, newly emerging infectious pathogenic diseases has influenced the need for effective vaccines across the globe. This has driven the R&D activities undertaken by the operational players as well as dedicated research institutes. Advancement in vaccine development technologies to increase its efficacy and liability will offer innovative solutions to address existing disease burden. The adoption of novel development approaches including DNA/RNA vaccines, nanoparticle vaccines, and rational design will foster the vaccines market expansion.

Vaccine Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Vaccine Market Report Findings

https://www.globalinsightservices.com/reports/vaccine-market/

The adult segment is likely to hold a dominant Vaccine Market share and grow at a substantial CAGR during the forecast period.

Based on age group, the market is bifurcated into Pediatric, and Adult. Adult vaccines segment is projected to proceed at xx% CAGR during the forecast timeframe. This is attributable to the increasing awareness about the importance of immunization and advancements in vaccine technology, more adults are actively seeking vaccination against various diseases. The rise in chronic conditions, such as heart disease, diabetes, and respiratory illnesses, has further propelled the demand for adult vaccines. Additionally, the COVID-19 pandemic has highlighted the critical need for adult vaccinations, leading to a surge in vaccine uptake. As a result, pharmaceutical companies and healthcare providers are focusing on expanding their adult vaccine portfolios and improving accessibility to cater to this growing market segment. Additionally, some countries have established the vaccination policies and regulations for adults while travelling to particular nations to avoid the risk of disease transmission, that has further influenced the vaccination rate in adults.

The Inactivated segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the technology, the market is bifurcated into Conjugate, Live, Inactivated, Recombinant, Toxoid. Vaccines market from inactivated segment exceeded USD xx billion in 2022. This is attributed to the ability of inactivated vaccines in destruction of pathogen replication. This offers effective protection against various dreadful pathogenic diseases such as hepatitis A, influenza, polio, and rabies. Moreover, these vaccines prevent the reversal activity of pathogens to more pathogenic phenotype and avoids the interference with other functional molecules during the combination therapies. This leads to preference for inactivated technology over the live vaccines. Furthermore, as it can stored without refrigeration for certain period as the pathogen is dead, it offers ease in transportation and storage that will continue to increase its demand.

The COVID-19 segment is anticipated to hold a majority of the Vaccine Market size throughout the study period.

Based on the application, the market is bifurcated into Cancer, Hepatitis, Pneumococcal Disease, Influenza, Rotavirus, COVID-19, and others. Among these the Covid-19 vaccine segment has experienced remarkable growth within the vaccine market. Since the emergence of the pandemic, the urgent need for effective vaccines has driven extensive research, development, and manufacturing efforts worldwide. The unprecedented global demand for Covid-19 vaccines has led to a surge in production and distribution capabilities, with numerous pharmaceutical companies, governments, and international organizations actively participating in the vaccination campaigns. This growth has been fueled by the imperative to curb the spread of the virus, alleviate the strain on healthcare systems, and restore economic stability. The Covid-19 vaccine segment’s rapid expansion has not only contributed significantly to saving lives and reducing the severity of the disease but has also propelled advancements in vaccine technology and infrastructure, fostering innovation and resilience in the broader vaccine market.

The Europe region is estimated to exhibit the highest growth rate during the Vaccine Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World.  Europe vaccines market accounted for xx% revenue share in 2022. This is attributable to the adoption of new technologies and expanding awareness about the preventive vaccines in the region. The government organizations are implementing some strategies to broaden accessibility for the emerging infectious disease treatments including the COVID-19. In addition, the industry players entered in collaboration with non-government organizations to provide COVID-19 vaccines considering significantly increasing disease incidence in the region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10524/

Competitive Landscape

The global Vaccine Market report includes players are AstraZeneca plc., CSL Limited, Emergent BioSolutions Inc., GlaxoSmithKline plc., Johnson & Johnson, Merck & Co., Novavax, Pfizer Inc, Sanofi S.A., and Serum Institute of India, among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In February 2021, Ceva partnered with the French National Research Institute for Agriculture, Food, and Environment (INRAE) for R&D in the prevention of infectious diseases from animal origin and improvement of animal health.
  • In January 2021, Zoetis launched the Poulvac Procerta HVT-IBD vaccine for the protection of poultry against Infectious Bursal Disease (IBD). This added to the company line of recombinant vector vaccines.
  • UNICEF and Pfizer entered into a supply agreement for the COVID-19 vaccines distribution throughout 2021. This has helped the company to maintain broaden its distribution across the globe, thereby driving the business revenue.

Vaccine Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Vaccine Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Vaccine Market potential from 2022 to 2032 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Vaccine Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Vaccine Market Segmentation

By Age Group

  • Pediatric
  • Adult

By Technology

  • Conjugated
  • Live
  • Inactivated
  • Recombinant
  • Toxoid
  • Others

By Application

  • Cancer
  • Hepatitis
  • Pneumococcal Disease
  • Influenza
  • COVID-19
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

Read More

Pharmacovigilance (PV) Market
May, 2023

Pharmacovigilance Market to Reach US$ 20.1 bn by 2033, driven by The faster credit approval processes and ease of accessing the online platforms: Global Insight Services

New York, March 2024: According to a new research study by Global Insight Services (GIS), the global Pharmacovigilance Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 20.1 bn by 2033.

Pharmacovigilance is the science and activities related to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problems. Passive surveillance is the most common type of pharmacovigilance activity. It is important because it can identify previously unknown adverse events. However, it has some limitations, such as under-reporting and reporting bias. Active surveillance is less common, but it is useful for monitoring drugs that are used to treat rare conditions. Experimental studies are the most reliable way to assess the safety of a new medicine, but they are usually only conducted during the development and approval process. Pharmacovigilance is a complex and ever-changing field. It requires close collaboration between healthcare professionals, patients and the pharmaceutical industry.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS22087/

Pharmacovigilance Market: Key Trends and Drivers

The key drivers of pharmacovigilance (PV) market are the increasing number of clinical trials, the growing prevalence of chronic and life-threatening diseases, and the need for better patient safety.

The number of clinical trials has been increasing over the years as the pharmaceutical industry seeks to develop new and better treatments for various diseases. This has led to an increase in the number of patients being exposed to new drugs, which has in turn led to an increase in the need for PV.

The prevalence of chronic and life-threatening diseases is also a key driver of the PV market. As the population ages, the number of people suffering from chronic diseases such as cancer and heart disease is increasing. This is leading to a greater need for PV, as these patients are often taking multiple medications that need to be closely monitored for safety.

Finally, the need for better patient safety is also driving the PV market. In recent years, there have been a number of high-profile cases of patients being harmed by drugs that were not properly monitored. This has led to calls for better PV, which is helping to drive the market.

Pharmacovigilance Market: Restraints & Challenges

The key restraints and challenges in Pharmacovigilance (PV) market include the following:

  • Lack of awareness of PV among patients and healthcare professionals: There is a lack of awareness of PV among patients and healthcare professionals. This is a challenge because it can lead to underreporting of adverse events and lack of data for safety monitoring.
  • Lack of standardization: There is lack of standardization in PV, which is a challenge because it can lead to inconsistency in data collection and analysis.
  • Limited resources: PV requires significant resources, which can be a challenge for many organizations.
  • Lack of trained personnel: There is a lack of trained personnel in PV, which is a challenge because it can lead to errors in data collection and analysis.

Pharmacovigilance Market Report Findings

https://www.globalinsightservices.com/reports/pharmacovigilance-pv-market/

The phase IV segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

Based on the clinical trail phases, the Pharmacovigilance market is divided into Preclinical I, phase I, phase II, phase III, phase IV. The phase IV (post-marketing) segment led the overall market  share in 2023. These solutions act as an additional safety measure for the drugs undergoing clinical trials. Phase IV is an imperative stage of clinical trials as unsuspected adverse drug reactions can be detected in this stage. Therefore, the data collected and assessed during this stage is expected to be of the highest relevance owing to intensive drug testing on a large patient base of highest relevance after commercialization of the drug.

The phase III segment is expected to witness lucrative growth in the forecast period. Phase III trials are done to determine and establish the efficacy of drugs. These trials also provide additional information regarding possible drug interactions, drug safety, and effectiveness before the commercialization of the drug. The aforementioned factors are expected to boost revenue generation in the segment over the forecast period

The Contract outsourcing segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

By service provider, the industry is bifurcated into In-house, and Contract Outsourcing. Contract outsourcing held the dominant revenue share of over xx% in 2023 and is expected to witness the fastest CAGR in the forecast period. This can be attributed to the benefits associated with outsourcing such as risk mitigation, resource flexibility, reduction of upfront investments, and lower fixed costs. Contract outsourcing organizations provide solutions such as process design Standard Operating Procedure (SOP), PV audits, and other customized services.

The dynamic growth of the contract outsourcing segment can also be attributed to the rapidly emerging CROs providing end-to-end clinical trial solutions, especially in the emerging economies of Asia Pacific, such as India, China, and Japan, thereby enabling resources sharing, cost efficiency, resource flexibility, and expansion of operative capabilities. Outsourcing PV services is accompanied by benefits such as delivering services pertinent to highly complex regulatory requirements, helping to add scalability to accommodate growing product portfolios, and achieving aggressive cost targets. Contract outsourcing also helps reduce the complexity of clinical trials, allows faster approval of trials, and helps effective utilization of internal resources.

The Spontaneous reporting segment is likely to hold a dominant Pharmacovigilance Market share and grow at a substantial CAGR during the forecast period.

Based on Type of Reporting, the industry is categorized into Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, and EHR Mining. Spontaneous reporting held the largest share of over xx% in 2023 owing to wide usage in the detection of new, serious, and rare ADRs. Moreover, this segment serves as an efficient and inexpensive method. Wide usage of surveillance reports generated through this method by pharmaceutical industries and regulatory authorities is also responsible for the significant growth of the segment.

Cohort Event Monitoring (CEM) emerged as the second-largest segment in 2023 owing to its increasing application in the detection of a wide range of adverse clinical events. Conjugation of CEM with statistical tools and data mining systems such as longitudinal health records are responsible for the growing popularity of this type. It serves as an active form of surveillance method, which can also be used for new as well as older medicines, thus driving the segment.

The pharmaceuticals lending segment is anticipated to hold a majority of the Pharmacovigilance Market size throughout the study period.

Based on end-user, the Pharmacovigilance market is divided into Pharmaceuticals, Biotechnology Companies, Medical Device Manufacturers, and Others. In 2023, pharmaceuticals held the largest revenue share of over xx%. Outsourcing the pharmacovigilance process is practiced by pharma companies to avoid high upfront investments and fixed overhead costs, increase resource flexibility, and secure additional capacity. Outsourcing pharmacovigilance proves to be a cost-effective endeavor for small and medium-sized companies.

The biotechnology segment is anticipated to witness lucrative growth in the forthcoming years owing to increasing new product development activities in this sector. In recent years, drugs are being developed and consumed at increasingly high rates. The use of drugs over longer periods by a large population can lead to adverse effects not seen in clinical trials. For instance, Vioxx (an osteoarthritic/ acute pain medication) and Avandia (an anti-diabetic) were marketed for some time before a pattern of safety problems was detected with their use. The growing need for medical information among the regulatory authorities is also anticipated to drive the segment.

The North America region is estimated to exhibit the highest growth rate during the Pharmacovigilance Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America holds a major market share for pharmacovigilance and is expected to continue its stronghold for a few more years. Since pharmacovigilance activities are being shifted to contract research organizations (CROs) due to high costs, the pharmacovigilance approach in the United States is moving from a passive to a proactive role in the healthcare system. As per the Institute of Medicine report, by Christopher Cheney, published in March 2020, nearly 98,000 Americans died annually due to medication errors. Estimates of annual patient deaths due to medication errors have since risen steadily to 440,000 lives, which makes medication errors the country’s third-leading cause of death. Therefore, there is a need to modify the current protocols for quick communication between healthcare providers and the Food and Drug Administration. Since pharmacovigilance plays a vital role in drug assessment and prevention of adverse effects, the demand for such services is likely to increase in the near future.

Have a question for our analyst

https://www.globalinsightservices.com/inquiry-before-buying/GIS22087

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global Pharmacovigilance market include Accenture, Cognizant, Laboratory Corporation of America Holdings, IBM Corporation, ArisGlobal, ICON plc., Capgemini, ITClinical, FMD K&L, and IQVIA among others.

Recent Developments in the Pharmacovigilance Market:

  • In December 2023, ArisGlobal, a prominent company in Life Sciences technology known for its LifeSphere® platform, has unveiled LifeSphere NavaX. This new offering is an advanced cognitive computing engine designed to speed up the digitization of research and development IT processes. It achieves this by utilizing sophisticated technologies such as Large Language Models (LLM) and Generative AI (Gen AI) to revolutionize pharmacovigilance (PV) activities.
  • In November 2023, Permira Advisers LLP has finalized the purchase of Ergomed plc for £703.1 million. Ergomed is a unique company specializing in Pharmacovigilance (PV) and contract research services (CRO), particularly focused on complex oncology and rare diseases. It is known for its excellent track record and customer-centric approach in delivering high-quality services. Ergomed operates in expanding markets that are seeing rising complexity, regulatory demands, and outsourcing trends. The company has enhanced its capabilities in both CRO and PV through organic growth and strategic acquisitions.
  • In November 2023, The National Agency for Food and Drug Administration and Control (NAFDAC) has announced that it has allocated a total budget of $2,305,695.03 for the Global Fund’s grant cycle 6. This allocation is aimed at enhancing operations and improving capacity, among other objectives. NAFDAC’s Director General, Prof Mojisola Adeyeye, shared during a press briefing in Abuja that a portion of this budget, specifically $36,965.00, has been dedicated to enhancing staff capabilities in pharmacovigilance strengthening and adverse drug reaction (ADR) monitoring.
  • In February 2022, Cognizant entered into a partnership with Medable Inc. to jointly deliver clinical research solutions based on Medable’s software-as-a-service platform for decentralized clinical trials.
  • In February 2022, LINK Medical and Viedoc entered into a partnership established by Viedoc and designed to improve trial efficiency for LINK Medical and its clients. The partnership allows for a continuous exchange of experience, needs, and ideas, as well as the testing of new features.
  • In November 2021, Deloitte and Sanofi collaborated on ConvergeHEALTH Safety, a next-generation artificial intelligence (AI) software-as-a-service adverse events case intake platform that will transform pharmacovigilance (PV) and address some of the industry’s most pressing operational safety issues.

Pharmacovigilance Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current Pharmacovigilance (PV) Market outlook and estimations from 2023 to 2033, which helps to recognize the prevalent opportunities.
  • The report also covers qualitative as well as quantitative analysis of the Pharmacovigilance (PV) Market in terms of revenue ($Million) and volume (Units).
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the Pharmacovigilance (PV) industry.
  • A thorough analysis of market trends and restraints is provided.
  • By region as well as country, market analysis is also presented in this report.
  • The Pharmacovigilance (PV) Market Study comprises an analysis of 23 countries. The research also encompasses a segment analysis of every country in terms of value (USD Million) throughout the study period.
  • Analytical depiction of the Pharmacovigilance (PV) Market along with current trends and future estimations to depict imminent investment pockets. The overall Pharmacovigilance (PV) industry opportunity is examined by understanding profitable trends to gain a stronger foothold.
  • Porter’s five forces analysis, SWOT analysis, Pricing Analysis, Case Studies, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Pharmacovigilance (PV) Market are also analyzed.
  • The report also involves market strategy factors such as the ANSOFF Matrix, 4Ps Model, Demand-Supply Analysis, Competition Product Analysis, Recent Developments, Consumer Buying Interest, and Supply Chain Analysis among others.

Global Pharmacovigilance Market Segmentation

By Clinical Trial Phase

  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Service Provider

  • In-house
  • Contract Outsourcing

By Type of Reporting

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

By End User

  • Pharmaceuticals
  • Biotechnology Companies
  • Medical Device Manufacturers
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa
Key Players

 

Read More

Ophthalmic Drugs Market
May, 2023

Ophthalmic Drugs Market to Reach US$ 68.574.4 mn by 2032, driven by include increasing incidences and prevalence of eye-related disorders, rising research and development about the development of novel drugs, and increasing focus on developing combination therapies: Global Insight Services

New York, May 2023: According to a new research study by Global Insight Services (GIS), the global Ophthalmic Drugs Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 68.574.4 mn by 2032.

The ophthalmic drugs are the formulations that are designed for the treatment of eye diseases such as cataract, glaucoma, color blindness, diabetic macular edema, cytomegalovirus (CMV) retinitis, and age-related macular degeneration (AMD).

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS21358

Ophthalmic Drugs Market: Key Trends and Drivers

Rise in Prevalence of Eye Disorders

In industrialized nations, the aging population increases life expectancy, and unfavorable changes in lifestyle, such as bad eating habits and reduced exercise, are anticipated to lead to a rise in the prevalence of illnesses that might impair eyesight in the future. The most frequent causes of visual impairment include hereditary retinal illnesses affecting young people, glaucoma, cataracts, and age-related macular degeneration, primarily among older folks. For instance, in October 2022, as per World Health Organization (WHO) facts on ‘Blindness and Vision Impairment,’ The yearly cost of productivity losses related to eye impairment is projected to be USD 411 billion, placing a tremendous financial burden on the whole world. However, vision loss may afflict people of all ages. The majority of persons with visual impairment and blindness are over the age of 50. A near- or distance vision impairment affects at least 2.2 billion individuals worldwide. Hence aforementioned factors will boost the market growth.

Ophthalmic Drugs Market: Restraints & Challenges

Challenges Associated with Formulation of Ophthalmic Drugs

One of the most difficult areas of the pharmaceutical industry, drug delivery to the human eye, is quickly expanding. It is challenging for medications to work at the site of action and endure over time due to the unique structure and physiology of the eye. Creating a therapeutic system that can deliver an ideal concentration of medication to the target region with high therapeutic efficacy is a challenge in ocular drug delivery systems. Due to the cornea’s architecture, physiology, and barrier properties, medicines are absorbed quickly; therefore, eye drop-inducing is necessary to maintain the therapeutic level in tear film or at specific spots. Consequences of utilizing medication solutions often include the potential for toxicity at the ocular surface and cellular damage.

Due to precorneal loss, including solution drainage, lacrimation, tear dynamics, tear dilution, conjunctival absorption, non-productive absorption, the temporary resident period in the cul-de-sac, and tear turnover, the majority of ocular dose forms have low bioavailability. Other difficulties include the impermeable corneal epithelial barrier, making it difficult to transport medications to the anterior area after topical administration.

Ophthalmic Drugs Market Report Findings

https://www.globalinsightservices.com/reports/ophthalmic-drugs-market/

The prescription segment is anticipated to hold a majority of the Ophthalmic Drugs Market size throughout the study period.

On the basis of product type, the global ophthalmic drugs market is segmented into prescription drugs, over the counter drugs. Among these, the prescription drugs segment is going to dominate the market over the forecast period. A prescription drug also known as prescription medication, prescription medicine or prescription-only medication) is a pharmaceutical drug that is only permitted to be dispensed to those with a medical prescription. The increased prevalence of illnesses such as AMD and diabetic retinopathy accounts for the expansion of the prescription medications category. Furthermore, improved efficacy and safety are two factors that are likely to drive prescription segment demand. Lotemax gel/ointment, Zylet, Durezol, bepreve (bepotastine besylate ophthalmic solution), and prescription synthetic tears are among the medications available in this market. Bepreve is an antihistamine used for the treatment of allergic conjunctivitis. Some prescription medications contain moisturizing and lubricating agents that temporarily increase tear secretion. Prescription drugs are thought to be more effective than over-the-counter treatments in treating ocular problems.

The dry eye segment is anticipated to hold a majority of the Ophthalmic Drugs Market size throughout the study period.

Based on disease, the industry is categorized into Eye Allergy, Eye Infection, Glaucoma, Retinal disorders, Dry Eye, Other. The dry eye segment is anticipated to witness the fastest growth during the forecast period. The segment was valued at USD 5,371.7 million in 2022 and it is expected to grow further to USD 11,919.8 million by 2032, at a rate of 7.9% during the forecast period. The factor such as the growing demand for effective treatments, the rising prevalence of dry eye disease, the presence of a lucrative pipeline, and increasing awareness among the population about the condition. The COVID-19 outbreak had an adverse impact on the market in the early phase of the pandemic attributable to the reduced ophthalmology visits. However, as soon as the eye care practices began the market demonstrated a rebound. Moreover, the dry eye persisted in SARS-CoV-2 patients even after treatment of the disease, thus, increasing the target population for treatments. Moreover, during the pandemic sedentary activities and more use of screen has increased the occurrence of dry eye symptoms. Increasing R&D activities for treating the condition have developed a strong and promising pipeline.

The topical segment is likely to hold a dominant Ophthalmic Drugs Market share and grow at a substantial CAGR during the forecast period.

Based on route of administration, the industry is categorized into oral, topical, and systemic. The topical segment was valued at USD 20,712.8 million in 2022 and it is anticipated to grow further to USD 39,786.5 million by 2032, at a CAGR of 6.4% during the forecast period. The factors which are the driving the topical segment are the rising demand for topical medicines due to easy doses, patient compliance issues, and different strategic initiatives performed by market participants account for the expansion of the topical sector. Suspensions, remedies, and ointments are common topical medication dose forms. The cornea is the principal route of topical absorption that faces substantial anatomical challenges. The availability of various medications administered topically is thought to be the primary driver of this market. For example, Allergan, an AbbVie Inc. subsidiary, reported in October 2021 that the US FDA has authorized VUITY for the treatment of presbyopia. Vuity is the only FDA-approved eye drop for the treatment of a variety of eye disorders. The topical route segment is expected to yield the most income throughout the anticipated term. Existing formulas are being replaced as more novel products are introduced to the market, which will drive market growth in the coming years.

The eye drop lending segment is anticipated to hold a majority of the Ophthalmic Drugs Market size throughout the study period.

Based on dosage form, the Ophthalmic Drugs market is divided into Gels, Eye Solutions & Suspensions, Capsules and Tablets, Eye Drops, and Ointments. The capsules and tablets segment was valued at USD 9,341.1 Million in 2022. Factor such as increasing health consciousness among the individuals coupled with advancements in manufacturing technology and the introduction of new materials. This will added more features to the traditional capsules such as controlled drug release, tamper-evident, and formulation choice of potent APIS due to reduced degradation in stomach pH, appealing aesthetics, and longer shelf life. In recent times, manufacturers are focusing on developing non-gelatin-based capsules using plant-based polymers. Starch, HPMC, and gums such as Pullulan. Increasing launch of tablet and capsule will fuel the segmental growth. For instance, In April 2022, Wellbeing Nutrition released “Melts Eye Care,” the world’s first all-natural eye vitamin.

The Anti-VEGF segment is anticipated to hold a majority of the Ophthalmic Drugs Market size throughout the study period.

Based on drug class, the Ophthalmic Drugs market is divided into Antiallergy, Anti-inflammatory, Anti-VEGF Agents, Anti-glaucoma, and Others. The Capsules and Tablets segment was valued at USD 9,341.1 Million in 2022. Factor such as increasing health consciousness among the individuals coupled with advancements in manufacturing technology and the introduction of new materials. This will added more features to the traditional capsules such as controlled drug release, tamper-evident, and formulation choice of potent APIS due to reduced degradation in stomach pH, appealing aesthetics, and longer shelf life. In recent times, manufacturers are focusing on developing non-gelatin-based capsules using plant-based polymers. Starch, HPMC, and gums such as Pullulan. Increasing launch of tablet and capsule will fuel the segmental growth. For instance, In April 2022, Wellbeing Nutrition released “Melts Eye Care,” the world’s first all-natural eye vitamin.

The North America region is estimated to exhibit the highest growth rate during the Ophthalmic Drugs Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the Ophthalmic Drugs Market growth, recording the highest CAGR during the forecast period. Among all other regions, North America holds the largest market share over the forecast period. There are numerous market players in the North American region, and as more individuals learn about the items’ accessibility, ophthalmic pharmaceutical sales will increase. Both the healthcare infrastructure and consumer knowledge are of the highest calibre in this region. These two elements will be essential to the market’s growth over the course of the projection period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS21358/

Competitive Landscape

Market players are focusing on strategic collaborations to enhance their product offerings. Some prominent participants in the global ophthalmic drugs market includes players such as Pfizer Inc., Sterling Pharmaceutical Services LLC, Somerset Pharma, LLC, Alcon Inc., Novartis AG, Bayer AG, Nicox SA, Coherus BioSciences, Inc., Sun Pharmaceutical Industries, Inc., Krishlar Pharmaceuticals, Allergan (AbbVie Inc), and others.

Recent Developments in the Ophthalmic Drugs Market:

  • In May 2023, Alcon launched TOTAL30® for Astigmatism, the first and only reusable contact lens with Water Gradient material for astigmatic contact lens wearers.
  • In September 2022, Alcon has announced new products introductions in the United States at AA). Clareon Toric IOL is introduced by Alcon, which is completing the Clareon Collection. Fidelis and patient involvement are expanding Alcon’s digital capabilities. Given international surgical backlogs and personnel limitations, the demand for remote, digital solutions in ophthalmology has never been stronger.
  • In April 2022, Sandoz announced the release of its generic combination eyedrop brimonidine tartrate/timolol maleate ophthalmic solution 0.2%/0.5%, an AB-rated generic counterpart to AbbVie’s COMBIGAN, to treat ocular hypertension (high eye pressure) in patients.
  • In March 2022, Nicox SA announced encouraging findings from a Chinese Phase 3 clinical trial of ZERVIATE (cetirizine ophthalmic solution), 0.24%, conducted by Ocumension Therapeutics, its Chinese partner. The antihistamine ZERVIATE has compared to emedastine difumarate ophthalmic solution, 0.05%, which is sold under the trade name EMADINE.

Ophthalmic Drugs Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Ophthalmic Drugs Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Ophthalmic Drugs Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Ophthalmic Drugs Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Ophthalmic Drugs Market Segmentation

By Product Type

  • Prescription Drugs
  • OTC Drugs

By Disease

  • Dry Eye
  • Eye Allergy
  • Glaucoma
  • Eye Infection
  • Retinal Disorders
  • Uveitis & Others

By Route of Administration

  • Topical
  • Local Ocular
  • Systemic

By Dosage Form

  • Gels
  • Eye Solutions & Suspensions
  • Capsules and Tablets
  • Eye Drops
  • Ointments

By Drug Class

  • Antiallergy
  • Anti-inflammatory
  • Anti-VEGF Agents
  • Anti-glaucoma
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Teva Pharmaceutical Industries Ltd.
  • Novartis AG
  • Pfizer Inc
  • Sun Pharmaceutical Industries, Inc.
  • Bayer AG
  • Alcon Inc.
  • Allergan (AbbVie Inc)
  • Coherus BioSciences, Inc.
  • Krishlar Pharmaceuticals
  • Nicox SA
  • Sterling Pharmaceutical Services LLC
  • Somerset Pharma, LLC

 

Read More

Proteomics Market
April, 2023

Proteomics Market to Reach US$ 68.4 Bn by 2032, driven by Increasing investment in research and development activities: Global Insight Services

New York, April 2023: According to a new research study by Global Insight Services (GIS), the global Proteomics Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 68.4 Billion by 2032.

Proteomics is the large-scale study of proteins, including their structure, function, and interactions. Proteins are the main components of cells and play a vital role in all biological processes. By understanding proteins, we can better understand how cells work and how diseases develop. Proteomics research often uses high-throughput techniques to analyze thousands of proteins at once. This allows us to identify patterns and trends that would be difficult to see using traditional methods. Proteomics has been used to discover new proteins, understand the function of existing proteins, and develop new drugs and diagnostic tests.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS20619/

Proteomics Market: Key Trends and Drivers

The rising prevalence of chronic diseases like cancer, Cardiovascular Diseases (CVDs), respiratory diseases, CKD, and others is another factor anticipated to propel the market growth. For instance, according to Globocan, in December 2020, there were 19.3 million new cases of cancer across the world and 10 million cancer-related deaths were reported. Similarly, CVDs are one of the major causes of death worldwide. For instance, as per the WHO (2021), target diseases kill 41 million patients per year. Thus, owing to the increasing prevalence of life-threatening diseases, the demand for personalized therapies is also increasing resulting in a positive impact on the industry.

Proteomics Market: Restraints & Challenges

Proteomics is the large-scale study of proteins, their structures and functions. It is a relatively new field, only coming into its own in the late 1990s with the advent of new technologies that allow for the rapid identification and characterization of proteins.

Despite its promise, proteomics faces a number of key challenges that must be overcome if it is to fulfill its potential. Perhaps the most significant challenge is the sheer size and complexity of the proteome. The human proteome is estimated to contain upwards of 20,000 different proteins, each with its own unique structure and function. Understanding the role of all of these proteins in health and disease is a daunting task.

Another challenge facing proteomics is the lack of standardization. Unlike genomics, which has benefited from years of research and standardization efforts, proteomics is still in its early stages. This lack of standardization makes it difficult to compare results across different studies and to replicate findings. Finally, proteomics is an expensive field of research. The cost of the necessary equipment and reagents can be prohibitive, making it difficult for many laboratories to get started in proteomics.

Proteomics Market Report Findings

https://www.globalinsightservices.com/reports/proteomics-market/

The Electrophoresis equipment segment is likely to hold a dominant Proteomics Market share and grow at a substantial CAGR during the forecast period.

By product, the market is segmented into Spectroscopy, Chromatography, Electrophoresis, Protein Microarrays, and Others. Electrophoresis equipment and biochip analyzers are the commonly used instruments for protein analysis. Furthermore, the increasing demand for automation in diagnostic techniques and the need for a cost-effective platform for sample analysishave increased interest among manufacturers to focus on innovations and product development. Moreover, technological breakthroughs (the growing downsizing and integration of biochips as well as advancements in the instruments and workflows for mass spectrometry) in proteomics instruments are expected to drive market trends over the years to come.

The drug discovery segment is anticipated to hold a majority of the Proteomics Market size throughout the study period.

By application, the proteomics market is classified into clinical diagnostics, drug discovery, and other application. The drug discovery segment dominated the global market with a revenue share of over xx% in 2022. On the other hand, the drug discovery segment is estimated to register the fastest growth rate during the projected period. The development of structure-based drug design, a greater emphasis on creating personalized drugs, and more investments in these areas can all be credited for the segment growth. In addition, proteomics technologies also offer a way to show early on in a drug discovery program, saving pharmaceutical corporations a significant amount of capital and eventually benefiting patients as well as the healthcare systems, which contributes to the segment growth.

The clinical laboratories segment is anticipated to hold a majority of the Proteomics Market size throughout the study period.

Based on end-user. It is segmented into hospitals, clinical laboratories, pharmaceutical companies, academic research laboratories, and others. Clinical laboratories was the market’s dominant segment in 2022. This is due to the widespread use of protein analysis by researchers and clinicians to identify illness biomarkers for early detection and detecting individual risk factors. This is expected to provide new avenues for disease early detection and prevention. It is feasible to discover prospective biomarkers and protein transcriptional regulation that can be used to identify and predict malignancies, as well as evaluate their prognosis, using proteomics-based diagnosis, which promotes the segment’s growth.

The North America region is estimated to exhibit the highest growth rate during the Proteomics Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The North American market is primarily driven by the rise in demand for the preservation of blood, solid tissue specimens, including paraffin-embedded or frozen bio-specimen of tumors, and other tissues (like peripheral blood cells, bone marrow, and stem cells-derived cord blood and its derivatives), across multiple research institutes, pathological centers, and hospitals. The surge in the government’s investment in drug discovery is projected to boost the biopreservation utility for the preservation of cells, tissues, and organs ex-vivo for the purpose of storage, shipment, and transportation. For instance, the Canadian government invested USD 45 million in the current year over the next three years to the Stem Cell Network to encourage stem cell and regenerative medicine research. Such investments are anticipated to boost the utility and demand of biopreservation in the region, thereby boosting market growth during the forecast period.

Additionally, advancements in technology, increasing product approvals, partnerships, and acquisitions by key players are helping in the market growth. For instance, in February 2022, OriGen Biomedical Inc., a global medical device manufacturer of cryopreservation, cell culture, and respiratory products, launched CryoStore FLEX Freezing Bag in the United States and Europe. The CryoStore FLEX Bag is designed for the cryopreservation of blood components and offers the multi-chamber flexibility of small-volume dose solutions.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS20619/

Competitive Landscape

The key players in the Proteomics Market are Agilent Technologies Inc., Danaher Corporation, LI-COR, Inc., PerkinElmer, Inc., Thermo Fisher Scientific, Inc., HORIBA, Ltd., Bio-Rad Laboratories, Inc., Bruker Corporation, General Electric (GE), and Waters Corporation, among others.

Recent Developments in the Proteomics Market:

  • In January 2022, The Proteograph Product Suite’s Broad Commercial Release and the Centers of Excellence program’s debut were both announced by Seer, Inc. The Proteograph Product Suite offers impartial, unmatched access to the proteome. The approach uses unique designed nanoparticles to produce a ground-breaking product that enables quick, thorough, and unbiased proteomics at scale.
  • In June 2021, Bruker Corp. launched the two new timsTOF instruments. It enables new methods & applications, such as epiproteomics/PTM characterization, and unbiased, and, deep multi-omic biomarker discovery.

Proteomics Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Proteomics Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Proteomics Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Proteomics Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Proteomics Market Segmentation

By Product

  • Spectroscopy
  • Chromatography
  • Electrophoresis
  • Protein Microarrays
  • Others

By Application

  • Clinical Diagnostics
  • Drug Discovery
  • Other Application

By End-user

  • Hospitals
  • Clinical Laboratories
  • Pharmaceutical Companies
  • Academic Research Laboratories
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Agilent Technologies Inc.
  • Danaher Corporation
  • LI-COR, Inc.
  • PerkinElmer Inc.
  • Thermo Fisher Scientific Inc.
  • HORIBA Ltd.
  • Bio-Rad Laboratories Inc.
  • Bruker Corporation
  • General Electric
  • Waters Corporation

 

Read More

Robot as a Service (RaaS) Market
March, 2023

Robot as a Service (RaaS) Market to Reach US$ 59.1 Bn by 2032, driven by growing demand for professional robots in a several industries: Global Insight Services

New York, March 2022: According to a new research study by Global Insight Services (GIS), the global Robot as a Service (RaaS) Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 59.1 Billion by 2032.

Robot as a Service (RaaS) is a cloud services unit that enables the seamless integration of robots and embedded devices into online and cloud computing environments. Customers and robotic enterprises both gain from robots as a service. Robots as a service enable businesses to reap the rewards of robotic process automation (RPA) by licensing robotic gear and utilizing a cloud-based subscription service. The key advantage of employing this technology is that it reduces the need for manual IT support while increasing the efficiency of robotic procedures. The deployment of a robot as a service in an organization is dependent on three factors: first, the use of proper tools to operate the robot as a service; second, determining the precise level of services needed by the company; and third, selecting a vendor to assist the robot as a service.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10534/

The growing need for professional robots in several sectors is predicted to boost the worldwide robot as a service market expansion during the forecast period. This is due to the growing demand for automated operations across a wide range of professional fields. Due to an increase in the impact of human assistance tasks, reduction of work pressure, and support of maximum reliability in repetitive activities in industries, RaaS is gaining popularity. The RaaS market is growing due to high demand for RaaS to monitor, control, and manage other activities in the food and beverages, defense, logistics, and other manufacturing sectors. Increased automation in manufacturing facilities to boost productivity is expected to boost the growth of global RaaS market.

Robot as a Service (RaaS) Market: Restraints & Challenges

Service robots have a high annual maintenance cost, which limits firms’ ability to invest, particularly small and medium-sized businesses. This is anticipated to stifle market expansion shortly. The market’s growth is projected to be limited by organizations’ unwillingness to migrate from manual to automated operations. Companies are using RPA solutions all over the world to optimize business operations. However, a lack of understanding of the technology is preventing RaaS from being adopted. Within the next two to three years, professional service providers plan to use RPA technologies in their organization.

Robot as a Service (RaaS) Market Report Findings

https://www.globalinsightservices.com/reports/robots-as-a-service-raas-market/

The professional robots segment is likely to hold a dominant Robot as a Service (RaaS) Market share and grow at a substantial CAGR during the forecast period.

By service, the market is divided into personal and professional. The professional robots category has a bigger market share and is predicted to increase at an exponential rate throughout the forecast period. This is mostly due to increased demand for service robots in areas such as defense, construction, medical, logistics, and others.

The logistics segment is anticipated to hold a majority of the Robot as a Service (RaaS) Market size throughout the study period.

By end-user, the market is classified into healthcare, BFSI, food & beverage, IT & telecom, retail, defense, media & entertainment, logistics, and others. Because of the automation brought by the act of moving and storing goods, the logistics segment has the largest stake. In addition, there is a growing need for service robots in order to streamline supply chain procedures across sectors. Medical service robots are expected to develop significantly as people turn toward incorporating robotic solutions for important medical procedures and with the advent of high-tech research facilities.

The Europe region is estimated to exhibit the highest growth rate during the Robot as a Service (RaaS) Market forecast period.

Europe dominates the global robot as a service market, owing to increased demand for personal and professional robots in numerous nations throughout the region. Europe has the highest concentration of manufacturers, at approximately 44 percent, due to rising demand from industries such as defense, medical, logistics, and retail. Following Europe, Asia Pacific held the second-largest share and is expected to grow at the fastest rate.

This is primarily due to increased R&D activity in the industrial robot industry, as well as increased government funding in robotics, automation, artificial intelligence, and other technologies. According to World Robotics 2018, over 35% of service robot manufacturers are present in North America, raising the potential growth of the market.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10534

Competitive Landscape

The key players in the market are KUKA AG, Parrot SA, Lely International, DJI, Northrop Grumman, Intuitive Surgical, Inc., Aethon Inc., Kongberg Maritime AS, Honda Motor Co. Ltd., and iRobot Corporation., among others.

Recent Developments in the Robot as a Service (RaaS) Market:

  • In July 2021, ABB purchased the ASTI Mobile Robotics Group in order to accelerate the development of flexible automation employing mobility devices. The acquisition strengthens the company’s Robotics and Machine Automation solutions, enabling it to offer a unique automation portfolio and expand into new business areas.
  • In April 2021, Panasonic Corporation has released a systematic model of their Walk Training Robot, which is intended to provide effective and safe walking training for older people. In addition, the company provides a robot-assisted solution to hospitals, institutions, and other organizations.

Robot as a Service (RaaS) Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Robot as a Service (RaaS) Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Robot as a Service (RaaS) Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Robot as a Service (RaaS) Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Robot as a Service (RaaS) Market Segmentation

By Services

  • Personal
  • Professional Others

By End-user

  • Healthcare
  • BFSI
  • Food & beverage
  • IT & Telecom
  • Retail
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • KUKA AG
  • Parrot SA
  • Lely International
  • DJI
  • Northrop Grumman
  • Intuitive Surgical, Inc.
  • Aethon Inc
  • Kongberg Maritime AS
  • Honda Motor Co. Ltd
  • iRobot Corporation
Read More

Laryngoscopes Market
March, 2023

Laryngoscopes Market to Reach US$ 1.5 Bn by 2032, driven by new product launches and strategic activities by major players: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Laryngoscopes Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 1.5 Billion by 2032.

Laryngoscopy is a medical device used in the visualization and examination of larynx. It is also used during tracheal intubation in patients requiring ventilator support and compose of blades, light source and handle. The two forms of laryngoscopy procedure are direct laryngoscopy and indirect laryngoscopy.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10533

Laryngoscopes Market: Key Trends and Drivers

Increasing disease burden of laryngeal diseases as well as infectious and chronic respiratory diseases in developing countries is a major factor contributing to the laryngoscopes market share. Laryngeal cancer is second most common respiratory cancer, and incidence rate of laryngeal cancer is rising majorly due to adoption of unhealthy lifestyle and increased consumption of alcohol and tobacco. According to the Centers for Disease Control and Prevention, in U.S. about 40 million adults smoke cigarettes, and around 4.7 million middle and high school students consume at least one tobacco product. Thus, increasing adult smoking rates and tobacco consumption has led to several laryngeal diseases. Additionally, according to the American Society of Clinical Oncology (ASCO), approximately 184,615 individuals were diagnosed with laryngeal cancer globally. Hence, increasing demand for laryngoscopes to treat such diseases will accelerate the industry growth in forecast period.

Laryngoscopes Market: Restraints & Challenges

The market growth is limited by the strict regulations imposed on these devices. Additionally, high cost of these devices is another aspect that is expected to limit the industry growth. Furthermore, miniaturization of newly developed fiber optic laryngoscope could generate numerous growth opportunities for the market in the coming years.

Laryngoscopes Market Report Findings

https://www.globalinsightservices.com/reports/laryngoscopes-market/

The Video Laryngoscopes segment is likely to hold a dominant Laryngoscopes Market share and grow at a substantial CAGR during the forecast period.

Based on product, the market is bifurcated into Fiber Optic Laryngoscopes, Video Laryngoscopes, and Standard/Conventional Laryngoscopes. Video laryngoscopes segment is estimated to grow at xx% CAGR over the anticipated time period. Growing awareness about advantages associated with use of video laryngoscopes over conventional laryngoscopes will foster the market demand. The advantages include enhanced laryngeal view, reduction in applied force, and higher rates of successful rescue after the failure of direct laryngoscopy. Additionally, video laryngoscopes reduce errors during intubation and improves learning, feedback for a patient being put on ventilator.

The reusable segment is anticipated to hold a majority of the Laryngoscopes Market size throughout the study period.

Based on the usability, the market is bifurcated into Reusable, and Single-use. Laryngoscopes market from reusable segment was accounted for more than USD xx million in 2022. Reusability of devices is an important factor influencing medical professionals’ and hospitals’ purchasing decisions. These devices are highly preferred due to more functionality than traditional laryngoscopes and ease of use. On the other hand, reusable laryngoscopes, are more expensive up front but do not need to be replaced as frequently.

The hospital segment is anticipated to hold a majority of the Laryngoscopes Market size throughout the study period.

Based on the end-use, the market is bifurcated into specialty clinics, hospitals, and others. The hospital segment held over xx% revenue share in 2022, owing to expanding number of hospitals among developing and developed countries. Additionally, availability of advanced video laryngoscopes and enhanced visualization is likely to contribute to the segment demand. With high penetration of hospitals and presence of healthcare professionals will bolster the laryngoscopes market progression.

The Europe region is estimated to exhibit the highest growth rate during the Laryngoscopes Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Europe laryngoscopes market exceeded USD xx million in 2022 and is predicted to witness enormous growth during analysis timeframe due to rising prevalence of respiratory diseases among geriatric population as well as in adults. Increasing consumption of tobacco, smoking and rising air pollution are some factors that trigger respiratory diseases. Moreover, increasing number of healthcare initiatives by several government and non-government organization in the region will accelerate the regional market growth.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10533

Competitive Landscape

The global Laryngoscopes Market report includes players are KARL STORZ GmbH & Co, Ambu A/S, Medtronic plc, Flexicare Medical, Penlon Limited, Rudolf Riester GmbH, Propper Manufacturing Co. Inc., Teleflex Incorporated, Verathon Inc, Venner Medical, Olympus Corporation, among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In November 2022, PROACT Medical launched an innovative new range of gas sampling lines along with their new line of single-use laryngoscopes in the European market.
  • In July 2022, Zsquare, a leading developer of high-performance, single-use endoscopes, announced that it received FDA clearance to market its first product, the Zsquare ENT-Flex Rhinolaryngoscope.

Laryngoscopes Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Laryngoscopes Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Laryngoscopes Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Laryngoscopes Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Laryngoscopes Market Segmentation

By Product

  • Fiber Optic Laryngoscopes
  • Video Laryngoscopes
  • Standard/Conventional Laryngoscopes

By Usability

  • Reusable
  • Single-use

By End-use

  • Hospitals
  • Specialty Clinics
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • KARL STORZ GmbH & Co
  • Ambu A/S
  • Medtronic plc
  • Flexicare Medical
  • Penlon Limited
  • Dodow (LIVLAB)
  • Rudolf Riester GmbH
  • Propper Manufacturing Co. Inc
  • Teleflex Incorporated
  • Verathon Inc,

 

Read More

Sleep Tech Devices Market
March, 2023

Sleep Tech Devices Market to Reach US$ 95.8 Bn by 2032, driven by high prevalence of sleep disorders is expected to increase the demand for sleep tech devices: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Sleep Tech Devices Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 95.8 Billion by 2032.

Sleep tech devices are designed for monitoring and improving the outcome in patients with sleep disorders such as sleep apnea, insomnia, narcolepsy, etc.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10532/

Sleep Tech Devices Market: Key Trends and Drivers

Increasing technological advancements in sleep trackers is one of the significant opportunities for the sleep tech devices market growth. Sleep trackers are becoming more sophisticated. For example, 2breathe is a smart device that is supposed to be worn around the waist before going to bed. The device can detect breathing and play tones to aid sleep, and it automatically shuts off when it detects snoozing. It’s linked to an app that shows how one slept every morning. Beddit, on the other hand, is a sleep sensor that consists of a thin rectangle that is placed beneath sleeper sheets. It then monitors a variety of parameters, including sleep, varying sleep stages, respiration rate, heart rate, and more.

Sleep Tech Devices Market: Restraints & Challenges

the market growth is limited by the strict regulations imposed on these devices. Additionally, high cost of these devices is another aspect that is expected to limit the industry growth. Furthermore, miniaturization of newly developed sleep trackers could generate numerous growth opportunities for the market in the coming years.

Sleep Tech Devices Market Report Findings

https://www.globalinsightservices.com/reports/sleep-tech-devices-market/

The non-wearables segment is likely to hold a dominant Sleep Tech Devices Market share and grow at a substantial CAGR during the forecast period.

Based on product, the market is bifurcated into wearables, and non-wearables. Sleep tech devices market from non-wearables segment accounted for xx% business share in 2022 and is set to register a significant CAGR through 2032 driven by growing demand for smart beds. This smart bed can monitor and modify its settings automatically to help sleep soundly all night. It adapts to one sleeping position in real time, gently conforming to side, back, or stomach profiles to make sleeping comfortable. The bed can also help fall asleep faster by warming feet.

The narcolepsy segment is anticipated to hold a majority of the Sleep Tech Devices Market size throughout the study period.

Based on the application, the market is bifurcated into insomnia, obstructive sleep apnea, narcolepsy, and others. Sleep tech devices market from narcolepsy segment held nearly xx% revenue share in 2022. This is owing to the growing cases of narcolepsy. Narcolepsy is a chronic sleep condition that usually begins in adolescence and is characterized by extreme daytime sleepiness with serious repercussions for the patient. According to Journal of Clinical Sleep Medicine the cases of narcolepsy per 100,000 population increased by 14%, i.e., from 38.9 in 2013 to 44.3 in 2016. Such factors are expected to facilitate the demand for sleep tech devices and medication.

The specialty centers segment is anticipated to hold a majority of the Sleep Tech Devices Market size throughout the study period.

Based on the distribution channel, the market is bifurcated into specialty clinics, direct-to-consumer, hospitals, and others. Sleep tech devices market from specialty centers segment will exhibit a CAGR of xx% during the forecast period. The demand for sleep tech devices has surged as the number of patients suffering from sleeping problems has also increased. Sleep difficulties are common among people with psychological illnesses, and often prefer to seek therapy at specialty clinics. Sleep tech devices, such as sleep trackers, are recommended by healthcare professionals working in specialist clinics to boost mental health in individuals. The segment is also likely to rise as people become more aware of sleep therapy sessions.

The Europe region is estimated to exhibit the highest growth rate during the Sleep Tech Devices Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe market accounted for the largest revenue share in the global market in 2022. Rising prevalence of sleep disorders in the region, owing to an ageing population and rising cases of depression and insomnia among adults. For instance, according to an NHS Inform research, roughly one in every three persons in the UK suffers with insomnia, that is especially prevalent among the elderly population. Furthermore, high disposable income and presence of leading industry players in the region contributes significantly to the regional business growth..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10532/

Competitive Landscape

The global Sleep Tech Devices Market report includes players are Casper Sleep Inc., Cadwell Industries Inc., Dreem, Beddit (Apple Inc.), Eight Sleep, Dodow (LIVLAB), Emfit Ltd., Fitbit Inc. (Google LLC), ResMed Inc., Koninklijke Philips N.V., Sleep Shepherd LLC, Oura Health Ltd., Sleepace, Xiaomi, Withings,, among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In May 2022, Huawei Vietnam launched three new generation smartwatches, Huawei Watch GT3 Pro, Watch fit 2 and Watch Kids 4 Pro. This smartwatch is equipped with advanced features such as health alerts, early sleep alerts, medication alerts, and positive mood and exercise volume information.
  • In February 2022, Redmi launched the Redmi Smart Band Pro equipped with features such as an AMOLED display and 50 meters of water resistance. In addition, it has a heart rate monitor and a SpO2 sensor that will enable blood oxygen monitoring and sleep monitoring..

Sleep Tech Devices Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Sleep Tech Devices Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Sleep Tech Devices Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Sleep Tech Devices Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Sleep Tech Devices Market Segmentation

By Product

  • Wearables
  • Non-Wearables

By Application

  • Insomnia
  • Obstructive Sleep Apnea
  • Narcolepsy
  • Others

By Distribution Channel

  • Specialty Clinics
  • Direct-to-Consumer
  • Hospitals
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Casper Sleep Inc
  • Cadwell Industries Inc.
  • Dreem
  • Beddit (Apple Inc.)
  • Eight Sleep
  • Dodow (LIVLAB)
  • Emfit Ltd.
  • Fitbit Inc. (Google LLC)
  • ResMed Inc.
  • Koninklijke Philips N.V.

 

Read More

Medical Equipment Financing Market
March, 2023

Medical Equipment Financing Market to Reach US$ 311.9 Bn by 2032, driven by rapid technological advancements combined with AI technology has leveraged the medical industry potential: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Medical Equipment Financing Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 311.9 Billion by 2032.

The need of time is staying up to date with advancements in medical equipment but it can be an expensive prospect. That’s why many health care professionals need medical equipment financing to obtain the tools and machines they need. A medical equipment loan or lease helps those professionals get the equipment they need to bring in new and returning patients, helping them increase cash flow and build their reserves. With the continuous advancement in medical technology, it has become a necessity to opt for the best-in-class medical equipment for excellent healthcare services. However, advanced diagnostic systems are expensive and are difficult for medical practitioners and hospitals to afford through their funds. There arises the need for medical equipment funding with low monthly instalments and flexible loan models.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10531/

Medical Equipment Financing Market: Key Trends and Drivers

Increasing acceptance of artificial intelligent technology has leveraged the medical industry potential. With this, there is an upgradation to new equipment with better features that provides superior treatment to the patients. For instance, according to the Equipment Leasing & Finance Foundation’s Report, in 2019, nearly 8 in 10 businesses that acquired equipment and software used at least one form of financing such as lease, secure loan, or line of credit. Therefore, acquiring medical equipment with medical equipment loans and leases has been made simple and easy.

Medical Equipment Financing Market: Restraints & Challenges

As their economies expand, equipment finance firms continue to face numerous challenges. Even while banks have more resources and are seeking chances in the medical equipment market, the majority of businesses have grown more capital-conscious. It is more likely that hospitals, clinics, and diagnostic centers will spend money to maintain their existing equipment than to purchase new ones..

Medical Equipment Financing Market Report Findings

https://www.globalinsightservices.com/reports/medical-equipment-financing-market/

The patient monitoring equipment segment is likely to hold a dominant Medical Equipment Financing Market share and grow at a substantial CAGR during the forecast period.

Based on equipment, the market is bifurcated into diagnostics equipment, therapeutic equipment, patient monitoring equipment, laboratory equipment, and medical furniture. Among these, the patient monitoring equipment segment exceeded USD xx billion in 2022. This is attributed to the increasing demand for patient monitoring equipment in developing countries to observe, report and analyze acute or chronic conditions used in hospitals and clinics. Additionally, increasing use of ECG devices to check heart’s rhythm and electrical activity will propel overall medical equipment financing market expansion. Furthermore, high availability of patient monitoring equipment in the market such as blood pressure monitors, electro-cardiograph (ECG) device, patient monitors, pulse oximeter, pulse watches, continuous glucose monitoring device, spirometers, and capnography, among others. This will fuel the market progression. Therefore, many firms incline towards medical equipment financing & leasing, and loans required for infrastructure.

The new medical equipment segment is anticipated to hold a majority of the Medical Equipment Financing Market size throughout the study period.

Based on the type, the market is bifurcated into new medical equipment, rental equipment, and refurbished equipment. Among these, new medical equipment segment surpassed USD xx billion in 2022. This is owing to adoption of artificial intelligence, blockchain, voice search, chatbots, and virtual reality in health technologies. Moreover, increasing costs of the medical equipment’s, leading doctors or healthcare firms incline towards loan to purchase an equipment, this also reduces the high interest rates regardless of any type and number of instruments. In addition, it also helps in preserving working capital and streamline operations in a modified manner. Therefore, growing adoption of new medical equipment will foster the overall market size.

The Hospital segment is anticipated to hold a majority of the Medical Equipment Financing Market size throughout the study period.

Based on the end-user, the market is bifurcated into hospitals, clinics, laboratories & diagnostic centers, and ambulatory surgical centers [ASCs]. Medical equipment financing market from hospital segment accounted for xx% business share in 2022 and is set to register a significant CAGR through 2032. This is due to the rising utilization of medical equipment financing practices that allows hospitals to purchase medical equipment at lower price. Similarly, equipment financing increases the working capital of hospitals with more available capital. This allows hospitals in hiring new doctors and clinicians along with investment in cybersecurity software. Moreover, hospitals prefer to opt for healthcare loan including infrastructure loan and working capital to avoid risks in the market. Thus, medical equipment financing reduces the risk and controls the overall financial situations. As a result, increased hospital investments around the globe will certainly have a positive impact on the industry growth.

The North America region is estimated to exhibit the highest growth rate during the Medical Equipment Financing Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe medical equipment financing market is expected to grow at xx% CAGR during the forecast period driven by the high cost of healthcare equipment. According to the Organization for Economic Co-operation and Development (OECD), in Europe, the healthcare spending per capita increased around 3% each year between 2013 and 2019 by adjusting the inflation. Similarly, growing demand for medical equipment financing coupled with presence of major market player including Meridian Group International, and Societe Generale S.A will accelerate the regional market trends..

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10531/

Competitive Landscape

The global Medical Equipment Financing Market report includes players are CMS Funding, Kabbage (American Express), Bajaj Finserv, TIAA Bank, Blue Bridge Financial, LLC, First American Healthcare Finance, HDFC Bank, HeroFinCorp, JPMorgan Chase & Co., National Funding, SMC Finance, Truist Bank, Societe Generale S.A., and Toronto-Dominion Bank., among others.

Recent Developments in the Market:

  • In February 2022, Toronto-Dominion Bank and First Horizon announced the signing of a new contract that will allow Toronto-Dominion Bank to completely acquire First Horizon. The deal is worth USD 13 billion and will help TD strengthen its hold in the global market
  • In December 2021, API Holdings Limited and Piramal Capital & Housing Finance entered a joint collaboration in which the latter will offer its digital platform Retailio to API Holding. This will allow the company to improve its financial assistance services to all stakeholders.
  • In July 2021, IFC and the Multilateral Investment Guarantee Agency (MIGA) launched a trade finance guarantee initiative to help low-income countries recover from the effects of the pandemic by supporting trade flows of critical goods, including food and medical equipment.
  • In May 2021, E. Healthcare and NSIA Banque Cote d’Ivoire announced a partnership with IFC’s Africa Medical Equipment Facility to strengthen the healthcare industry and support medical equipment financing across Africa.
  • In April 2021, IMAGEENS jointly raised $1.45 million in seed funding with Anaxago. This is expected to strengthen the company’s team with key R&D talent to expand the deployment of software solutions.

Medical Equipment Financing Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Medical Equipment Financing Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Medical Equipment Financing Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Medical Equipment Financing Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Medical Equipment Financing Market Segmentation

By Equipment

  • Laboratory Equipment
  • Therapeutic Equipment
  • Diagnostics Equipment
  • Patient Monitoring Equipment
  • Medical Furniture

By Type

  • Refurbished Equipment
  • Rental Equipment
  • New Medical Equipment

By End-usee

  • Hospital
  • Clinics
  • Laborateries &Diagnostic Centers
  • Ambulatory Surgical Centers [ASCs]

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • CMS Funding
  • Kabbage (American Express)
  •  Bajaj Finserv
  • TIAA Bank
  • Blue Bridge Financial, LLC
  • First American Healthcare Finance
  • HDFC Bank
  • HeroFinCorp
  • JPMorgan Chase & Co.
  • National Funding
  • SMC Finance

 

Read More

Compartment Syndrome Monitoring Devices Market
March, 2023

Compartment Syndrome Monitoring Devices Market to Reach US$ 409.7 Million by 2032, driven by increasing investments in research-based projects and growing alliances among leading companies and research centers for drug discovery, and increasing inclination toward next-generation sequencing methods for identifying, treating, and monitoring chronic diseases: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Compartment Syndrome Monitoring Devices Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 409.7 Million by 2032.

The compartment syndrome monitoring devices refer to medical equipment that is employed for monitoring the compartmental pressure that assists in detection of compartment syndrome. These devices are specialized equipment that are increasingly employed in monitoring acute, chronic, and abdominal compartment syndrome.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10530/

Compartment Syndrome Monitoring Devices Market: Key Trends and Drivers

Technological developments in compartment pressure monitoring devices and the advent of a collaborative technique for promoting the operationality & precision of these devices will foster the business landscape. Better understanding of the pathophysiology of compartment syndrome and notable developments in compartment syndrome monitoring devices have improved the diagnosis of compartment syndrome & is expected to reduce the disease morbidity. The application of innovative diagnostic modalities including near-infrared spectroscopy (NIRS), radiofrequency identification (RFID) implants, and biomarker analysis is estimated to fuel the user preference.

The emergence of RFID implants, a novel technology that employs radio frequency electromagnetic waves for transferring data would assist the clinicians. Hence, the RFID sensors are in demand and being used in compartment syndrome monitoring devices. Furthermore, the product development and commercialization by major market players is set to prove beneficial for market growth.

Compartment Syndrome Monitoring Devices Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Compartment Syndrome Monitoring Devices Market Report Findings

https://www.globalinsightservices.com/reports/compartment-syndrome-monitoring-devices-market/

The disposable segment is likely to hold a dominant Compartment Syndrome Monitoring Devices Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into Disposables, and Equipment. Disposables segment is anticipated to witness xx% CAGR from 2022 to 2032 due to the rising preference for single-use and disposable equipment. Disposable medical supplies lower the risk concerned with hospital-acquired infection (HAI) by delivering better protection against transmission and contamination. The increasing usage and surged demand for sustainable medical solutions will stimulate the market share.

The Chronic compartment syndrome segment is anticipated to hold a majority of the Compartment Syndrome Monitoring Devices Market size throughout the study period.

Based on the syndrome type, the market is bifurcated into Acute Compartment Syndrome, Chronic Compartment Syndrome, and Abdominal Compartment Syndrome. Chronic compartment syndrome segment surpassed USD xx million in 2022 and is likely to register xx% CAGR from 2022 to 2032. This is owing to the substantial prevalence of chronic compartment syndrome. This is also known as chronic exertional compartment syndrome (CECS) that refers to a condition that majorly occurs due to exertional or repetitive loading activities. CECS is commonly profound among athletes such as long-distance runners, football players, skiers, and basketball players.

The Clinics segment is anticipated to hold a majority of the Compartment Syndrome Monitoring Devices Market size throughout the study period.

Based on the end-use, the market is bifurcated into Hospitals, Clinics, and Others. Clinics segment accounted for xx% revenue share in 2022 and is projected to progress at % CAGR during the forecast period. This is pertaining to the surging preference and steady transition towards clinics. The demand for these healthcare settings is surging with high application rate of novel compartment syndrome monitoring devices. Furthermore, the shift in the preference towards clinics due to several advantages including rapid assistance and cost-effective services have substantially impacted the segment growth. Clinics are regarded as a preferable alternative for preventive care and effective management of chronic conditions as they feature low waiting periods.

The North America region is estimated to exhibit the highest growth rate during the Compartment Syndrome Monitoring Devices Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the North America market accounted for the largest revenue share in the global market in 2022. North America has a large regional market in terms of revenue. The increasing prevalence of genetic and chronic disorders, such as cancer, the aging population, the growing demand for targeted and personalized medicine, and favorable government initiatives are the primary factors behind the growth of the whole-exome sequencing market. According to the HIV.gov updates in October 2022, HIV affects around 1.2 million persons in the United States. In the United States, in 2020, 30,635 persons were diagnosed with HIV. Thus, the growing burden of infectious diseases is expected to increase in demand for its diagnosis, thereby boosting the market’s growth over the forecast period.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10530/

Competitive Landscape

Some of the major players operating in the compartment syndrome monitoring devices industry are Millar, Inc., MY01, Inc., Critical Care Diagnostics (C2DX), Inc., Potrero Medical, Medline Industries, Becton, Dickenson, and Company, and ConvaTec. These players are involved in mergers & acquisitions, partnerships, and distribution agreements to gain competitive advantage over their competitors.

Recent Developments in the Blood-Brain Barrier Market:

  • In September 2022: Potrero Medical received FDA Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with IAH in cardiac post-surgical intensive care patients.
  • In July 2022: Sentinel Medical Technologies launched TraumaGuard Monitoring Device, a hands-free monitoring device designed to continuously measure real-time IIP and Core Body Temperature (CBT) in critical care patients.
  • In March 2022, C2Dx, another industry leader, announced the acquisition of Hemostatix Medical Technologies LLC, a medical device specialist. The acquisition complemented C2Dx’s plans to enhance the delivery of niche medical products around the world.

Compartment Syndrome Monitoring Devices Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Compartment Syndrome Monitoring Devices Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Compartment Syndrome Monitoring Devices Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Compartment Syndrome Monitoring Devices Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Compartment Syndrome Monitoring Devices Market Segmentation

By Product

  • Disposables
  • Equipment

By Technology

  • Acute Compartment Syndrome
  • Chronic Compartment Syndrome
  • Abdominal Compartment Syndrome

By Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Millar, Inc.
  • MY01, Inc.
  • Critical Care Diagnostics (C2DX), Inc.
  • Potrero Medical
  • Medline Industries
  • Boston Scientific Corporation
  • Becton, Dickenson, and Company
  • ConvaTec.
  • Hemostatix Medical Technologies LLC,
  • Biometrix Ltd. (3i Group plc)

 

Read More

Hemostasis Products Market
March, 2023

Hemostasis Products Market to Reach US$ 2.7 Bn by 2032, driven by increase in number of surgeries such as orthopedic surgery, gynecological surgery, reconstructive surgery, and cardiac surgery; rise in in various cancer types that require surgical procedures; and development of new hemostasis product market by large number of key players: Global Insight Services

New York, March 2023: According to a new research study by Global Insight Services (GIS), the global Hemostasis Products Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 2.7 Billion by 2032.

Hemostat is referred to a surgical agent that regulates and controls the bleeding process during surgical procedures. Hemostats help to shorten surgery time and reduces the need for blood transfusion. Hemostatic agents are essential in establishing hemostasis in pre-hospital conditions and preventing death associated with hemorrhage. Hemostats are used to compress blood vessels and prevent the flow of blood or other fluids. They are generally used in adjunct to surgical procedures to manage bleeding. Hemostatic agents offer different benefits, which include decreased wound healing & operative time, better management of anti-coagulated patients, and reduction in the patient recovery period boosting the hemostasis market.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10529/

Hemostasis Products Market: Key Trends and Drivers

Rise in flowable hemostats usage boosts the flowable hemostats market. According to the International Osteoporosis Foundation, in 2019, approximately 200 million people were affected by osteoporosis-related fractures across the globe. Thus, rise in burden of orthopedic disorders increases the demand for hemostats to reduce surgical injuries, which is anticipated to foster the growth of the hemostats market size. Furthermore, rise in geriatric population notably contributes toward the growth of the market. This is attributed to the fact that aged individuals are highly susceptible to various types of diseases, which increases the need for surgeries, thus boosting the hemostats market share. Furthermore, increase in number of road accidents has led to surge in surgical procedures, which augmented the growth of the hemostats market. According to the World Health Organization, in 2019, approximately 235 million major surgical procedures were performed across the globe. According to the National Cancer Statistics, in 2020, there were 1,806,590 new cases of cancer in the U.S. Therefore, surge in number of surgeries is anticipated to boost the growth of the market. According to the American Society of Plastic Surgeons, 15.6 million cosmetic surgeries were performed in 2020. Furthermore, increase in number of product approvals is expected to provide lucrative hemostats market opportunity for the expansion during the hemostats market forecast period. Thus, rise in hemostats utilization in surgeries is bound to increase hemostasis market potential.

Hemostasis Products Market: Restraints & Challenges

Some of the market obstacles include a scarcity of experienced specialists and significant investment costs, as well as legal and ethical concerns about the market methods and outcomes in numerous nations.

Hemostasis Products Market Report Findings

https://www.globalinsightservices.com/reports/hemostasis-products-market/

The Infusible hemostasis products segment is likely to hold a dominant Hemostasis Products Market share and grow at a substantial CAGR during the forecast period.

Based on Product, the market is bifurcated into Topical Hemostasis Product, Infusible Hemostasis Product, and Advanced Hemostasis Product. Infusible hemostasis products segment surpassed USD xx million in 2021. This is attributable to the growing number of patients suffering from cardiac diseases such as myocardial infarction, coronary heart disease, aortic disease etc. Cardiovascular disease is responsible for majority of deaths in countries such as India. It accounts for more than 25% of total deaths occurring in the country. Thereby, stimulating the product demand.

The Hemostat agents segment is anticipated to hold a majority of the Hemostasis Products Market size throughout the study period.

Based on the application, the market is bifurcated into Trauma, Surgery, Hemophilia, Myocardial Infarction, Thrombosis, and Others. Hemostat agents, such as products containing thrombin, are a safe and effective alternative to gelatin sponges and oxidized cellulose in controlling bleeding during surgeries. Hemostatic agents containing thrombin and collagen are superior to surgical hemostasis alone in controlling microvascular bleeding during cardiac surgery. It is also reasonable to use fibrin sealants as an adjunct to surgical hemostasis to limit bleeding in cardiac and aortic surgery.

As per the research study published in June 2021, titled “German Heart Surgery Report 2020: The Annual Updated Registry of the German Society for Thoracic and Cardiovascular Surgery”, a total of 92,809 operations were classified as heart surgery procedures in the classical sense, of which 29,444 were isolated coronary artery bypass grafting procedures, 35,469 were isolated heart valve procedures, and the number of isolated heart transplantations increased by 2% to 340. Additionally, according to the British Heart Foundation’s February 2021 report, about 371,000 heart procedures and operations were performed in England in 2020. Hence, the high number of heart surgeries and operations being performed every year may boost demand for hemostat agents that control bleeding.

The Hospitals segment is anticipated to hold a majority of the Hemostasis Products Market size throughout the study period.

Based on the end-use, the market is bifurcated into Hospitals, Clinics, and Others. The increase in hospital visits and growing expenditures on hospital care can be attributed to the growth of the hospital segment. Hospital spending climbed 6.4% amounting to USD 1,270.1 billion in 2020, the National Health expenditure data sheet states. This was an increase from the 6.3% growth in 2019. Additionally, there were almost 130 million hospital visits in the United States. Few of the well-known market leaders in the global hemostasis products market that are profiled by Research Nester are Pfizer Inc., Integra LifeSciences Corporation, Baxter, Medtronic, Stryker, BD (Becton, Dickinson and Company), Biom’up Innovative Surgery, Johnson & Johnson Services, Inc., CryoLife, Inc., Hemostatis LLC, and others.

The Asia Pacific region is estimated to exhibit the highest growth rate during the Hemostasis Products Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the market growth in Asia Pacific is elevated by rising instances of road accidents followed by rise in blood donations in the region. According to the Ministry of Road Transport & Highways under Government of India, in 2022, the country witnessed 3,66,138 road accidents, leading to 1,31,714 losses of lives and 3,48,279 people injured. 18-45 years’ age group is the prime group caught up in road accidents, which accounts for nearly 70% of total accidental deaths. Furthermore, in Japan, 400 mL blood donations are expected to result in an estimated 1.3 million liters of blood being donated in 2020. Additionally, from 1998 to 2020, blood donation increases by 40 folds in China and in 2020, there were approximately 16 million blood donation in the country.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10529

Competitive Landscape

The global hemostasis products market is moderately fragmented and consists of a number of major players. Companies like Abbott Laboratories, Baxter International, Inc., C. R. Bard, Inc. (BD), CSL Behring LLC, Dexur, Grifols, S.A., Johnson & Johnson, Medtronic plc, Pfizer, Inc., and Tricol Biomedical, among others, hold the substantial market share in the Hemostasis Products market.

Recent Developments in the Blood-Brain Barrier Market:

  • In May 2022, Precision BioLogic Inc., a developer of hemostasis diagnostic products, reported the launch of its new cryocheck Chromogenic Factor IX assay in Canada, the European Union, and the United Kingdom, Australia, and New Zealand.
  • In February 2022, Futura Surgicare Pvt Ltd expanded its product portfolio by launching hemostatic products under the brand Hemostax (Oxidised Regenerated Cellulose) under a new vertical, Dolphin Hemostats. Hemostax Standard is an absorbable hemostat designed to help surgeons control bleeding more efficiently.

Hemostasis Products Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Hemostasis Products Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Hemostasis Products Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Hemostasis Products Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global Hemostasis Products Market Segmentation

By Product

  • Topical Hemostasis Product
  • Infusible Hemostasis Product
  • Advanced Hemostasis Product

By Technology

  • Trauma
  • Surgery
  • Hemophilia
  • Myocardial Infarction
  • Thrombosis
  • Others

By Application

  • Hospitals
  • Clinics
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Abbott Laboratories
  • Baxter International, Inc.
  • C. R. Bard, Inc. (BD)
  • CSL Behring LLC
  • Dexur
  • Boston Scientific Corporation
  • Grifols, S.A.
  • OraSure Technologies, Inc.
  • Johnson & Johnson
  • Medtronic plc
  • Pfizer, Inc.
  • Tricol Biomedical
Read More

pH Meters Market
March, 2023

pH Meters Market to Reach US$ 2.4 Bn by 2032, driven by Rising demand for these devices in industries such as food processing, water treatment, power, agriculture, fertilizers, etc.: Global Insight Services

New York, February 2023: According to a new research study by Global Insight Services (GIS), the global PH Meters Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 2.4 Billion by 2032.

pH meters are instruments that are used to measure hydrogen-ion activity to determine acidic and alkaline levels in solutions. They are calibrated with known pH levels of solutions before use to ensure the accuracy and precision of results. They are used to ensure acidic levels in various applications ranging from water treatments to laboratories.

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10527

PH Meters Market: Key Trends and Drivers

Growing incidences of microbial infections coupled with technological advancements in pH meters are expected to serve as lucrative growth opportunities for this market. Moreover, the increasing number of research and testing laboratories such as soil testing, water testing, and food testing laboratories is also one of the factors, expected to boost the usage of these devices.

PH Meters Market: Restraints & Challenges

Many pH meters are soluble only in low conductivity solutions especially in distilled, deionized and ultrapure water. Continuous drift, frequent calibration and short service life will result from pH glass dissolution. The dissolving process will only accelerate at elevated temperature. There are no data available for selecting the right electrode, trial and error will provide the answer such uncertainties may hamper the market.

PH Meters Market Report Findings

https://www.globalinsightservices.com/reports/ph-meter-market/

The bench top pH meters segment is likely to hold a dominant PH Meters Market share and grow at a substantial CAGR during the forecast period.

By product type, the market is segmented into benchtop, and portable pH meters. Technological advancements such as online pH meters, calibration-free measurement systems, microprocessors for auto temperature, and pressure compensation are few of the factors that are expected to propel the market growth over the next seven years. In 2022, bench top pH meters held over xx% of the overall pH meters market owing to, its wide application in academic institutes, laboratories, industrial researchers, ease of usage, and growing demand for easy accessibility and accuracy. Portable pH meters are expected to witness a lucrative growth of over 7% during the forecast period of seven years. High mobility and small size of these meters is one of the key factors attributing to its rapid growth. Stringent regulations on water treatment plants by various EPA (Environmental Protection Agency), rising health concern among the population regarding adverse effect of quality of water and easy accessibility & availability of such instruments are among few of the factors that are expected to boost the usage of pH meters across various industries.

The manual type segment is anticipated to hold a majority of the PH Meters Market size throughout the study period.

By type, the pH meters market is segmented into digital and manual type pH meter. The manual type of pH meter segment has accounted for around USD xx million in 2022. This is owing to increasing adoption of manual pH meters as these types are mainly used in food and beverages and pharmaceutical industry to measures acidity/alkalinity of a solution. pH meters are also used to measure the acidity for preserving foods and fermentation process and it gives better operational control. Therefore, the demand for manual pH meters will boost.

The food and beverages segment is anticipated to hold a majority of the PH Meters Market size throughout the study period.

Based on end-use, the market is categorized into pharmaceutical and biotechnology companies, food and beverages, environmental testing, government and academic institutions, chemicals and petrochemicals, water, and wastewater treatment and others. Among these, the food and beverages segment are projected to witness xx% CAGR from 2022 to 2032. The demand for measuring pH meters in food and beverages industry for maintaining quality, safety, and consistency in food and beverages is increasing annually. Measuring pH value is one of the parameters measured during an inspection of the product before release. For instance, during cheeses-making, enzymatic activity is highly dependent on pH for improving yield and enhancing flavor.

Additionally, controlling pH regulates the growth of desirable and non-desirable microorganisms. Thus, to maintain different types of food such as acidified food, fermented food, and low-acid canned food, resulting in an increase in demand for pH meter thereby, driving the overall market statistics.

The North America region is estimated to exhibit the highest growth rate during the PH Meters Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. Among regional markets, the Europe pH meters market is expected to grow at xx% CAGR over the forecast period. The regional growth is attributable to the technological advancement integrated within the pH meter and rising regulatory landscape in developed as well as developing countries. Further, increasing incidences of water borne diseases will spur the regional market statistics. For instance, according to the European Centre for Disease Prevention and Control (ECDC), in 2018, Europe countries reported 26 confirmed cases of cholera.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10527

Competitive Landscape

Some of the prominent industry players operating in the pH meters industry include Thermo Fisher Scientific, Contech Instruments, Emerson Electric Co. (Rosemount Analytical), Hach, Qingdao Tlead International, Hamilton Company, PCE Instruments, Hanna Instruments, Inc., Panomex Inc., Shanghai Selon Scientific Instrument Co., Ltd., Horiba, Jenco Instruments Inc., Metrohm AG, TECPEL CO., LTD., Agilent Technologies, and Mettler-Toledo International Inc., among others.

Recent Developments in the Blood-Brain Barrier Market:

  • In March 2020, Metrohm AG launched new handheld 913 pH/DO Meter. This pH meter can measure pH value and concentration of dissolved oxygen within the same sample.
  • In 2017, Mettler Toledo, one of the leading global precision instruments manufacturer, launched Pro2Go, a smart handheld PH meter. The portable PH meter provides accurate and fast measurement, single-handed operational capabilities, and great durability.

PH Meters Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global PH Meters Market outlook and estimations from 2022 to 2032, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future PH Meters Market potential from 2022 to 2032 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the PH Meters Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global kidney stones management market.

Global PH Meters Market Segmentation

By Product

  • Bench top pH Meters
  • Portable pH Metersystem

By Type

  • Digital
  • Manual

By End-use

  • Pharmaceutical and Biotechnology Companies
  • Food and Beverage
  • Environmental Testing
  • Government and Academic Institutions
  • Chemicals and Petrochemicals
  • Water and Wastewater Treatment
  • Others

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • Thermo Fisher Scientific
  • Contech Instruments
  • Emerson Electric Co. (Rosemount Analytical)
  • Hach
  • Qingdao Tlead International
  • Hamilton Company
  • QIAGEN
  • PCE Instruments
  • Hanna Instruments, Inc.
  • Panomex Inc

 

Read More

Biodefense Market
March, 2023

Biodefense Market to Reach US$ 40.7 Bn by 2032, driven by rising demand for better flexibility in Service Level Agreements (SLAs) and convenience in change management procedures together with cost-cutting: Global Insight Services

New York, March 2022: According to a new research study by Global Insight Services (GIS), the global Biodefense Market is expected to grow rapidly over the next 10 years to reach a value of more than the US $ 40.7 Billion by 2032.

Biodefense can be defined as the activity of preparing for, responding to and countering the acts of bioterrorism. A bioterrorism attack involves the deliberate release of bacteria, viruses and other pathogens that can cause chronic illnesses to humans, animals, agriculture and the environment. Biodefense involves various medical measures that are undertaken to protect individuals against biological threats, such as administering vaccinations and medicinal drugs, along with conducting research and various public health procedures. Biodefense products are commonly effective against anthrax, smallpox, botulism, radiation/nuclear disasters and other such catastrophes..

Request Sample Pages of this Research Report:

https://www.globalinsightservices.com/request-sample/GIS10528

Biodefense Market: Key Trends and Drivers

Growing investments by government will augment the overall market progression

Growing investments by government in R&D that encourages pharmaceutical and biopharmaceutical companies to boost the production of vaccines will propel the biodefense market share. Increasing global biological threats has created need for funds to support the R&D activities. Government authorities’ stock large amounts of vaccines and bio-threat detection devices to combat against the deliberate virus attacks. For instance, as per the FDA FY 2023 budget, investment of USD 1.6 billion over five years has been allocated for biodefence vaccines and development of biodefense diagnostic devices. Therefore, growing investments in biodefense enables biopharmaceutical companies to manufacture technologically advanced biothreat detection devices that will significantly drive the industry outlook.

Biodefense Market: Restraints & Challenges

KPO industry faces challenges like shortage of manpower and knowledge issues concerns for data security and poor infrastructure, and rise in real-state costs. All of these factors combined tend to be huge challenges for the industry to grow and prosper. For example, the KPO industry requires professionals with the right skill-sets and domain knowledge but there’s a shortage of such professionals especially in developing economies.

Biodefense Market Report Findings

https://www.globalinsightservices.com/reports/biodefense-market/

The anthrax segment is likely to hold a dominant Biodefense Market share and grow at a substantial CAGR during the forecast period.

By product, the biodefense market is segmented into anthrax, botulism, smallpox, radiation/nuclear, and other products. The anthrax segment held the largest market share of xx% in 2022 and is expected to grow at a significant CAGR over the forecast period. Based on products, the market is segmented into anthrax, smallpox, botulism, radiation/ nuclear, and others. Bacillus anthracis is a gram-positive bacterium that causes anthrax. It is one of the most likely to be used potential weapons for a bioterrorist attack. These spores are mostly preferred as they can be easily released into the environment by placing them in food, water, powder, and sprays.

They can last for a long time in the environment and are easily found in nature (soil, plants, or water). According to NCBI, anthrax bacteria is categorized as a tier-1 biological agent as it can be easily transmitted from one person to another and holds the potential for a major public health tragedy. Countermeasures against anthrax remain one of the key areas for countermeasures. It has received major funding for vaccine development. This includes project bioshield, which has witnessed over USD 50 billion in funding since the September 11 attack in the United States. Many companies have their vaccine for anthrax in clinical trials.

The other product segment is expected to be the fastest-growing segment with a 6.2% CAGR over the forecast period. It includes viruses like include viral hemorrhagic fever, brucellosis, cholera, influenza, plague, food poisoning, tularemia, Zika, Ebola, and many others. The National Institute of Allergy and Infectious Diseases (NIAID) has a Vaccine Research Centre (VRC), which is working on VHF vaccines since 2003, especially against Ebola and Marburg viruses. The University of Texas at San Antonio (UTSA) has been awarded a contract from the U.S. Department of Defense (DoD) to develop a vaccine against tularemia. Tularemia being highly infectious and at times fatal in nature is a potential option for a bioweapon. Recently many countries are witnessing rising infection cases due to the zika and ebola viruses and therefore many companies are competing to develop its vaccine. MVA-BN Filo, manufactured by Bavarian Nordic, is a vaccine against two filoviruses, Ebola, and Marburg’s diseases, and is currently under phase 3 clinical trials and has collaborated with the U.S. NIAID for the same.

The Asia-Pacific region is estimated to exhibit the highest growth rate during the Biodefense Market forecast period.

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the Biodefense market capturing an xx% market share in 2022 and is expected to showcase a significant CAGR in the forecast period. This is attributed to the presence of high federal funding, technological advancements, and growing awareness among the population. The presence of major players in this region is also a favorable prospect for the biodefense market in 2022. Based on Federal Research and Development (R&D) in the fiscal year 2017, out of the total federal R&D funding that was received by eight federal agencies, 96.3% of it was received by the Department of Defense (39.3%) and the Department of Health and Human Services (27.3%) combined accounting for more than two-thirds of all federal R&D funding. This percentage of funding to DoD is proposed to increase to 48.4% in 2019. The introduction of the National Biodefense Strategy in 2018, with the purpose to detect and contain biothreats at their source. The policy also aims to support and promote biomedical innovation, and improve emergency response in case of biological outbreaks. These are some of the factors contributing to the high market growth in the region.

Asia Pacific is expected to witness the highest CAGR of 9.1% over the forecast period due to surging investments in R&D. The growing significance of biodefense, and the rising threat of harmful biological materials that engender emergencies is driving the market growth. Australia and Japan are two of the most mature Asia Pacific biodefense industry as it has well-established vaccine production facilities in the country. This coupled with the presence of sophisticated healthcare infrastructure in the country contributes to its market position. Countries like India and China are rigorously expanding their R&D capabilities to cater to biological threats in the future. China is the second country after the U.S to spend the largest percentage of its GDP on R&D. These are the factors that are expected to boost the biodefense industry in the region.

Have a question for our analyst:

https://www.globalinsightservices.com/inquiry-before-buying/GIS10528

Competitive Landscape

The key players in the market are XOMA corporation; Altimmune Inc. Emergent Biosolutions Inc.; Dynavax Technologies Corporation; SIGA Technologies; Elusys Therapeutics Inc.; Ichor Medical Systems; Dynport Vaccine Company; Cleveland Biolabs; Bavarian Nordic; Ology Bioservices; Alnylam Pharmaceuticals Inc. among others.

Recent Developments in the Biodefense Market:

  • June 2022: Emergent BioSolutions Inc. (NYSE:EBS) announced that the United States Food and Drug Administration (FDA) accepted for review the Biologics License Application (BLA) for AV7909 (Anthrax Vaccine Adsorbed, Adjuvanted).
  • May 2022: Emergent BioSolutions Inc. announced that it has entered into a definitive agreement with Chimerix, Inc. to acquire Chimerix’s exclusive worldwide rights to TEMBEXA (brincidofovir), the first antiviral approved by the United States Food and Drug Administration (FDA) for all age groups for the treatment of smallpox.
  • In April 2022, Heat Biologics, Inc. announced the completion of its acquisition of Elusys Therapeutics, Inc., a commercial-stage biodefense firm and developer of the anthrax therapy ANTHIM (obiltoxaximab). ANTHIM is approved for use in the United States and Canada, as well as in Europe and the United Kingdom, under the brand name Obiltoxaximab SFL.
  • in January 2022, integrated Viral Protection (IVP), a Texas-based technology business, released a new portable air filtration equipment that can eliminate airborne viruses in a single pass, including sub-micron versions producing COVID-19, anthrax spores, allergens, and other dangerous respiratory triggers.

Biodefense Market Report Coverage

  • The report offers a comprehensive quantitative as well as qualitative analysis of the current global Biodefense Market outlook and estimations from 2021 to 2031, which helps to recognize the prevalent opportunities.
  • A thorough analysis of market trends and restraints is provided.
  • Region-wise, as well as country-wise conditions, are broadly evaluated in this report.
  • The forecasts in this report are made by examining the recent trends along with future Biodefense Market potential from 2021 to 2031 in terms of revenue.
  • Porter’s five forces analysis, SWOT analysis, COVID-19 impact analysis, Russia-Ukraine war impact, and PESTLE analysis of the Biodefense Market are also analyzed.
  • Major players in the market are profiled in this report and their key developmental strategies are studied in detail. This will provide an insight into the competitive landscape of the global surface disinfectants industry.

Global Biodefense Market Segmentation

By Product

  • Anthrax
  • Botulism
  • Smallpox
  • Radiation/Nuclear
  • Other Products

By Region

  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Rest of World
    • Latin America
    • Middle East
    • Africa

Key Players

  • XOMA corporation
  • Altimmune Inc.
  • Emergent Biosolutions Inc.
  • Dynavax Technologies Corporation.
  • SIGA Technologies.
  • Elusys Therapeutics Inc.
  • Ichor Medical Systems.
  • Dynport Vaccine Company.
  • Cleveland Biolabs.
  • Bavarian Nordic.

 

Read More